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Polycystic ovary syndrome (PCOS) is the leading cause of anovulatory infertility in women. 
Disordered folliculogenesis in PCOS has long been characterized by three phenomena: (1) the 
accumulation of small follicles, (2) inhibition of follicular maturation, and (3) absence of follicular 
turnover. These defects presumably prevent ovulation, but have never been explored in vivo. An 
accurate understanding of antral follicle development in PCOS is critical to facilitate the diagnosis 
and identify targets for nutritional and pharmacologic interventions aimed at reinstating ovulation. 
The central objective of this dissertation was to characterize antral folliculogenesis in women with 
PCOS. In Part 1, we used serial ultrasonography to assess follicle growth and regression during 
a 4–5-week interval. Anovulatory cycles were considered in Chapter 1. We documented active 
components of follicle development amidst follicular excess in PCOS, and revealed that follicles 
become arrested at the mid-antral stage, but turnover more frequently than in normal ovaries. 
Sporadic ovulatory cycles were considered in Chapter 2. We observed earlier selection in women 
with PCOS than in regular ovulatory cycles and identified potential relationships between milder 
reproductive features and likelihood of sporadic ovulation. In Part 2, we began to explore the 
implications of disordered antral folliculogenesis on the diagnosis of PCOS and treatment of 
anovulation. The clinical utility of the sonographic criteria for PCOS were considered across the 
menstrual cycle in Chapter 3. We demonstrated that diagnostic markers of follicular excess are 
robust over time irrespective of cycle phase. Nutritional therapies for anovulation were reviewed 
in Chapter 4. We described the limitations of previous studies and identified opportunities for 
future research in the field. Collectively, this dissertation integrated ultrasonographic approaches 
from basic science to inform and improve the clinical management of women with PCOS.
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PREFACE 
 
 Polycystic ovary syndrome (PCOS) affects one in ten women of reproductive age and is 
the leading cause of ovulatory dysfunction globally.1,2 The condition is complex and influenced by 
a variety of factors, including age, ethnicity, genetics, and environment.3 PCOS imparts significant 
consequences for reproductive (anovulation, androgen excess, infertility, pregnancy-related 
risks), metabolic (obesity, insulin resistance, type 2 diabetes mellitus, metabolic syndrome, 
cardiovascular disease), and psychological (anxiety, depression, poor quality of life) health across 
the lifespan.4 Reproductive disturbances are often the best-recognized features and are 
consequently relied on to diagnose the condition and guide the selection of treatments that can 
address infertility.5 
 
Diagnosis of PCOS 
 Diagnosis of PCOS is largely based on the Rotterdam criteria6,7 and the presence of two 
of three cardinal features: oligo- or anovulation, androgen excess, and polycystic ovaries.8,9 Other 
disorders that cause ovulatory dysfunction or androgen excess (e.g. thyroid abnormalities, 
hyperprolactinemia, nonclassical congenital adrenal hyperplasia) are excluded.7 PCOS can be 
categorized into four different phenotypes based on the possible combinations of the cardinal 
features: (A) Frank (oligo- or anovulation, androgen excess, polycystic ovaries), (B) Non-PCO 
(oligo- or anovulation, androgen excess, normal ovaries), (C) Ovulatory (regular ovulatory cycles, 
androgen excess, polycystic ovaries), and (D) Normoandrogenic (oligo- or anovulation, normal 
androgen status, polycystic ovaries) (Table P.1).8,9  
 PCOS exists on a spectrum and varies in prevalence and severity among the four 
phenotypes. The hyperandrogenic phenotypes (Table P.1, Columns A–C) are the most common 
in consecutive patient and unselected populations10–12 and represent the severest end of the 
spectrum. Androgen excess is positively associated with degree of reproductive dysfunction10–12 
xi 
and confers increased risk for chronic metabolic diseases.13 The normoandrogenic phenotype 
(Table P.1, Column D) is less common.10–12 Inclusion of this variant is controversial,14,15 because 
androgen excess has been considered a cornerstone of the syndrome since its first description 
in 1935.14–17 However, multiple studies have shown that the combination of oligo- or anovulation 
and polycystic ovaries is associated with mild reproductive and endocrine features of PCOS.10–12 
Women with Normoandrogenic PCOS may have decreased risk for chronic metabolic disease, 
but further studies are needed to corroborate these data.13,18 
 
Table P.1. PCOS phenotypes enabled by the Rotterdam criteria 
 Frank (A) Non-PCO (B) Ovulatory (C) Mild (D) 
Oligo- or anovulation Yes Yes No Yes 
Androgen excess Yes Yes Yes No 
Polycystic ovaries Yes No Yes Yes 
Prevalence10 66% 9% 13% 11% 
Abbreviations: PCOS, polycystic ovary syndrome; PCO, polycystic ovaries.  
  
 Assessment of the cardinal features of PCOS is challenging.18 The features are treated 
as dichotomous variables, but the optimal analytical technique is controversial and diagnostic 
thresholds remain largely undefined.4,6,7,18 Consequently, clinicians and researchers rely on tools 
readily available at their sites and often establish thresholds based on internal normative ranges 
for each marker. Multiple professional societies have responded to these challenges with general 
recommendations for the assessment and definition of each feature.7–9,14,15,19 Generally, oligo- or 
anovulation is judged by self-report of irregular menstrual cycles and confirmed in cases of 
eumenorrhea with biochemical evidence of anovulation (e.g. low serum progesterone during the 
suspected luteal phase).7–9,14,15 Clinical or biochemical androgen excess is evaluated by physical 
examination of male-patterned hair growth (termed hirsutism) or elevated serum androgens  (e.g. 
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total testosterone).7–9,14,15 Polycystic ovaries are identified on ultrasonography by increased follicle 
number and/or ovarian size.8,9,19,20  
 
Normal Ovarian Folliculogenesis 
 This dissertation focused on the mechanism of anovulation in PCOS. An overview of the 
normal process of ovarian folliculogenesis is necessary to understand the existing evidence and 
rationale for these studies. Broadly, ovarian follicles are cellular structures that contain immature 
oocytes, and folliculogenesis is defined as the process of follicular growth and atresia within the 
ovaries.21,22 Proper follicle development relies on signals from the hypothalamus, pituitary, and 
ovary and is essential for the maturation of a healthy gamete and baby.22,23 
 
Hypothalamic-Pituitary-Ovarian Axis 
 The hypothalamic-pituitary-ovarian axis coordinates female reproductive function.23  The 
hormones produced by the anterior pituitary and/or ovaries provide feedback at the level of the 
hypothalamus and pituitary to regulate hormone production during the menstrual cycle.  
 Gonadotropin-releasing hormone (GnRH) is a peptide hormone synthesized and released 
from neurons in the hypothalamus. GnRH is released in a pulsatile manner into the pituitary portal 
network.24 At the anterior pituitary, the hormone stimulates the synthesis and release of the 
gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These 
processes are controlled by the size and frequency of GnRH pulses.24 Slow GnRH pulse 
frequencies promote FSH synthesis, whereas fast GnRH pulse frequencies promote LH 
synthesis.25,26  
 FSH and LH are glycoprotein hormones produced in the gonotrophic cells of the anterior 
pituitary.23 At the ovary, LH binds to LH receptors located on the membrane of follicular thecal 
cells, granulosa cells at later stages of development (i.e. ≥10 mm), and luteinized theca and 
granulosa cells of the corpus luteum (CL).27 LH binds to theca cells at all stages of development 
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to stimulate ovarian androgen production (e.g. testosterone).28 LH binds to granulosa cells of 
larger follicles to stimulate granulosa cell proliferation, growth, and estradiol production.21,23,29 
Luteinized cells of the CL also stimulate progesterone production during the luteal phase.30 By 
contrast, FSH binds to FSH receptors located on the cell surface of granulosa cells. It stimulates 
aromatase activity, increases granulosa cell proliferation, and induces the growth of follicles to 
the mid-antral stage. FSH is suppressed by estradiol and progesterone (described below).21,23 In 
antral follicles >6 mm, aromatase converts androgens produced in theca cells to estrogens (e.g. 
estradiol).31,32  
 Estradiol is a steroid hormone synthesized from cholesterol and produced by the 
granulosa cells of antral follicles. Estradiol at low concentrations provides negative feedback to 
the anterior pituitary, thereby suppressing gonadotropin secretion and continued follicle growth. 
Estradiol at high concentrations may provide positive feedback to the pituitary, but the 
mechanisms of this action are still uncertain.29 Progesterone is a steroid hormone synthesized in 
the luteinized granulosa and theca cells of the pre-ovulatory follicle and CL. It is mainly under the 
control of LH and provides negative feedback to the anterior pituitary, thereby suppressing 
gonadotropin secretion during the luteal phase.30 
 
Ovarian Follicular Development 
 Folliculogenesis is a very long process in women.33 It begins as early as the fourth month 
of embryonic development, when somatic cells surround the oocytes and form primordial 
follicles.27,34 Follicles at this stage are arrested in meiosis and comprise the ovarian reserve, which 
provides a woman with reproductive potential for her lifetime. Depletion of the ovarian reserve 
begins during gestation and continues through menopause.34 Prior to puberty, primordial follicles 
progress from the resting (0.03 mm) to growing state (0.06 mm) (Figure P.1). This process takes 
approximately five months; some follicles initiate growth immediately, while others remain 
quiescent for years.35–37 Pre-antral follicles (0.06–0.2 mm) grow independent of gonadotropin 
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support. The process takes approximately six months.33,27 Follicles then form a fluid-filled cavity 
(i.e. antrum) at a diameter of 0.2–0.4 mm and become responsive to gonadotropins. Follicles 
undergo atresia (or regression) in the absence of gonadotropins.27,35 Maturation of the 
hypothalamic-pituitary-ovarian axis at puberty enables the cyclic development of antral follicles to 
2 mm or larger38 (Figure P.1). The presence of an antrum allows this process to be visualized on 
ultrasonography.22,39 Descriptions of the stages of folliculogenesis are provided in more detail 
below.  
 
Figure P.1. Normal ovarian folliculogenesis in women. Distinct phases, key events, and overall 
timing of folliculogenesis are depicted. Follicular graphics were obtained from Ansh Labs. 
 
 
 
 
 
 
 
 
 
 
Pre-Antral Phase 
 Primordial (or resting) follicles are 0.03 mm in diameter and characterized by a single layer 
of flattened granulosa cells.33 Activation of follicular growth to the primary stage (0.06 mm) 
involves the proliferation and differentiation of the granulosa cells, as well as the actions of 
multiple hormones and growth factors.22,27,40 Follicular growth is driven by further replication of the 
granulosa cells and an acquisition of theca cells.21 At the secondary stage (0.1 mm), the follicular 
vasculature develops, and the granulosa and theca cells begin to express receptors for 
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gonadotropins and ovarian steroid hormones.27,33,35 Pre-antral follicles are gonadotropin-
sensitive, but their development is largely mediated by paracrine and autocrine factors secreted 
from the oocyte and surrounding cells.37  
 
Antral Phase 
 At the early antral stage (0.2–2 mm), an antrum forms from fluid collections within the 
follicle.41 Antral follicles then progress towards ovulation through three physiologic classes: (1) 
small (2–5 mm), (2) medium (6–9 mm), and (3) large (≥10 mm). Such growth is dynamic, and 
reflects continued replication of the granulosa cells, wherein each class is distinguished by the 
number of granulosa cells present.33  
 A cohort of small antral follicles (2–5 mm) is “recruited” from the pre-antral pool at least 
once during the menstrual cycle.35,42 The process of recruitment typically occurs once during the 
late-luteal or early follicular phase.35 These follicles are dependent on gonadotropins for continued 
growth and will undergo atresia in the absence of sufficient stimulation.21 Atresia occurs via 
apoptosis, which is a form of programmed cell death. During the reproductive years, >99% of 
growing follicles will undergo atresia, whereas only 1% will ovulate.34 An increase in circulating 
concentrations of FSH above a critical threshold is required to stimulate antral follicle growth to 
the mid-antral (6–9 mm) stage.43  
 Medium antral follicles grow synchronously with one another until a single dominant follicle 
(≥10 mm) is “selected” for preferential growth. Multiple cohorts of medium antral follicles may 
emerge and regress throughout the menstrual cycle, but the process of selection occurs once in 
the early- to mid-follicular phase, thereby leading to ovulation.43,44 The dominant and largest 
‘subordinate’ follicles undergo a common growth phase in women. At the time of selection, the 
dominant follicle begins to ‘diverge’ as it continues to grow, while the remaining follicles undergo 
atresia.42–44 Dominant follicle selection is associated with a decrease in circulating concentrations 
of FSH and an increase in circulating concentrations of estradiol.29  
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 Estradiol synthesis by the selected follicle is preceded by LH-stimulated androgen 
production in theca cells. Aromatization of androgens to estradiol within the growing follicle 
increases local and systemic estradiol concentrations.26 Estradiol produced by the dominant 
follicle stimulates proliferation of the endometrial lining in preparation for ovulation and 
subsequent conception.27 Estradiol production also increases LH pulse frequency, which drives 
aromatase activity. Increased aromatase activity induces LH receptors on granulosa cells and 
causes the follicle to switch from FSH to LH-dependent growth.29 Notably, inappropriate LH 
production or stimulation can inhibit further follicular growth and disrupt oocyte maturation.32 
 The dominant follicle grows at an accelerated rate after selection and attains a pre-
ovulatory diameter of 16–29 mm in the late follicular phase.43–45 Granulosa and theca cells 
continue to proliferate and antral volume increases.27 The persistently elevated serum estradiol 
concentration triggers an LH surge from the anterior pituitary. The LH surge induces final 
maturation and ovulation of the oocyte from the dominant follicle.21,29  
 A sharp decline in estradiol and increase in progesterone production occurs as enzymes 
and proteases work to degrade the follicular wall. The granulosa and thecal cells rearrange into 
the CL.30 Luteal development involves significant growth and differentiation. Luteinized theca and 
granulosa cells gain the ability to produce progesterone and retain their abilities to synthesize 
androgens and estradiol.30 Angiogenesis represents a significant portion of luteal growth, as the 
primary function of the CL is to synthetize and secrete progesterone, which nurtures the 
endometrial lining to provide a conducive environment for implantation.29,30  
 If these events do not occur, the CL undergoes luteolysis (or involution) via apoptosis.29,30 
The corresponding decrease in progesterone and estradiol causes atrophy of the endometrial 
blood supply and the endometrium begins to degrade.30 This process is referred to as 
menstruation. The decrease in progesterone and estradiol also result in an increase in FSH 
production from the anterior pituitary, which signal the start of the next cycle.23  
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Current Model of Impaired Folliculogenesis in PCOS 
 Defects have been identified across the hypothalamic-pituitary-ovarian axis in PCOS.46,47 
Pulsatile secretion of gonadotropin-releasing hormone from the hypothalamus is persistent and 
rapid in this condition.25 This pattern favors the synthesis of LH by the anterior pituitary and 
contributes to an increased LH: FSH ratio.48 High levels of LH49 and increased activity of 
steroidogenic enzymes50 augment ovarian androgen production in polycystic ovaries, whereas 
low levels of FSH likely inhibit follicular growth.46,47 Serial endocrine dynamics have never been 
described in PCOS. However, patients often demonstrate abnormal endocrine profiles, including 
elevated circulating concentrations of LH and androgens, and reduced serum concentrations of 
FSH.51,52  
 Polycystic ovarian morphology reflects aspects of disordered folliculogenesis in PCOS.47 
The morphological hallmark is an increased number of growing follicles, from the primary stage 
(0.06 mm) to the antral stage (2–5 mm) (Figure P.2).53–55 Histologic studies have confirmed that 
polycystic ovaries contain 2–3 times more primary, secondary, and small antral follicles than 
normal ovaries.53–55 Specifically, primary follicles are “stockpiled” in this condition.54,55 Pre-antral 
“follicular excess” may arise from increased activation of follicular growth from the primordial 
pool,54 slower maturation of primary follicles,55 and/or decreased atresia.56 Simultaneously, 
ultrasonographic studies have revealed a paucity of medium- and large antral follicles in polycystic 
ovaries.57 Larger follicles are presumably arrested in development due to impaired theca and 
granulosa cell function (Figure P.2).46,47 
Namely, theca cells from polycystic ovaries have shown an enhanced capacity to produce 
androgens in response to luteinizing hormone (LH).49 Androgens may then promote theca and 
granulosa cell proliferation and stimulate excessive growth to the selectable stage (2–5 mm).47 
Further, granulosa cells from polycystic ovaries have shown premature responsiveness to LH in 
follicles as small as 4 mm. This implies the early acquisition of LH receptors, which in normal 
ovaries, does not occur until the time of selection (i.e. at ~10 mm).22,58 The theory is that these 
xviii 
functional abnormalities collectively result in an inhibition of terminal follicular growth at the 6–9 
mm stage.47,46 Androgens may further inhibit atresia after follicles stop growing and therefore 
contribute to a state of follicular “persistence.”59,60 Together, these abnormalities are thought to 
inhibit selection and ovulation (Figure P.2).46,47 
 
Figure P.2. Current model of impaired folliculogenesis in PCOS. Proposed abnormalities in 
distinct phases and key events of folliculogenesis are depicted. Up and down arrows refer to 
increased and decreased activity, respectively, and “X’s” refer to absent events. Follicular 
graphics were obtained from Ansh Labs. 
 
 
 
 
 
 
 
 
 
 
 The corollary to follicular excess, arrest, and persistence is the concept that selection and 
ovulation cannot occur in women with PCOS.47,46 However, these phenomena do not provide a 
unanimous explanation for the disordered antral folliculogenesis in this condition, because some 
follicles can periodically ovulate during natural cycles or be “rescued” through pharmacologic 
intervention.47,46  
 
Rationale for the Current Studies 
 Longitudinal studies are ultimately needed to corroborate the degree to which antral follicle 
development is impaired in PCOS. To that end, a prospective cohort study was conducted to 
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characterize antral folliculogenesis in women with anovulatory phenotypes of PCOS. Owing to 
our observation of anovulatory and sporadic ovulatory cycles, Part 1 of this dissertation aimed: 
(1) To determine the extent to which follicular excess, arrest, and persistence are consistent 
findings in PCOS (Chapter 1); and (2) To evaluate the growth kinetics of ovulatory follicles, and 
(3) To identify the clinical factors that are associated with sporadic ovulation in PCOS (Chapter 
2).  
 Part 2 of this dissertation built on our new understanding of antral folliculogenesis and 
ovulatory potential in PCOS (Part 1) to guide diagnostic and treatment strategies better in this 
condition. Follicular excess is assumed to be a constant feature over time, and metrics that reflect 
follicle number are recommended to define polycystic ovarian morphology on ultrasound.19 
However, it is unclear whether follicle development during anovulatory or sporadic ovulatory 
cycles can confound the potential of sonographic markers to detect PCOS consistently. Thus, 
Part 2 of this dissertation aimed to evaluate any impact of a dominant follicle or a corpus luteum 
on the morphologic diagnosis of PCOS (Chapter 3). Moreover, because most patients are 
overweight or obese,61 modest weight loss (5–10%) is recommended to improve the likelihood of 
ovulation, both naturally and in response to assisted reproduction therapies.62 Data on the 
significance of sporadic ovulation are limited (Chapter 2), but are necessary to understand the 
extent to which current first-line strategies can actually impact ovulatory function in women with 
PCOS. As such, Part 2 of this dissertation further aimed: (1) To assess the evidence surrounding 
the effectiveness of hypocaloric dietary intervention to normalize ovulatory cyclicity, and (2) To 
provide recommendations to strengthen research in this area (Chapter 4).
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CHAPTER 1 
A NEW MODEL OF ANTRAL FOLLICULOGENESIS IN  
ANOVULATORY WOMEN WITH POLYCYSTIC OVARY SYNDROME 
 
ABSTRACT 
 
Objective. On ultrasonography, polycystic ovarian morphology is characterized by an abundance 
of small and medium-sized antral follicles. It is posited that antral follicles accumulate in the 
polycystic ovary as the result of impaired follicular maturation and decreased atresia. These 
phenomena have long been implicated in the mechanism of anovulation in polycystic ovary 
syndrome (PCOS), but have never been explored in vivo. The objectives of this study were to 
evaluate antral follicle development in women with PCOS and determine the degree to which 
follicular excess, arrest, and/or persistence are consistent findings in the condition.  
 
Methods. Women with PCOS (n=11) and regular ovulatory cycles (n=11) were prospectively 
evaluated by serial transvaginal ultrasonography. Antral follicle number and diameter (≥2 mm) 
were quantified every other day for 4–5 weeks. Follicle size populations and growth kinetics were 
compared between groups.  
 
Results. Antral follicle counts were substantially greater in women with PCOS compared to 
Controls on any given day (105 vs. 49 follicles, P<0.01). Differences between groups were driven 
by a higher number of both 2–5 mm (P<0.01) and 6–9 mm follicles (P=0.02) in women with PCOS. 
Antral follicle development in PCOS appeared disorganized, with numerous follicles randomly 
emerging and regressing throughout the scanning interval. Uniquely identified follicles grew to 
smaller maximal diameters in women with PCOS compared to Controls (10 vs. 23 mm, P<0.01). 
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This reflected shorter growth phases (P<0.01), but similar static (P=0.87) and regression phases 
(P=0.07). Overall, growth and regression rates did not differ between groups.  
 
Conclusions. Antral follicle growth and regression can be detected on ultrasonography in women 
with PCOS, despite the failure of dominant follicle selection and ovulation. Documentation of more 
frequent turnover of follicles in polycystic versus normal ovaries challenges the traditional theory 
of follicular persistence in PCOS.  
3 
INTRODUCTION 
Polycystic ovary syndrome (PCOS) is the main cause of ovulatory dysfunction in women, 
but the mechanism of anovulation is unknown. Most insight into disordered folliculogenesis in 
PCOS has been garnered from histologic studies of pre- and early antral follicles. Authors have 
described an “excess” of small follicles,53,55,54 and the premature “arrest”58,63 and “persistence” of 
larger follicles.59,60 However, very few studies have focused on advanced stages of follicular 
development (i.e. ≥2 mm); actual disruptions in selection and dominance have remained largely 
unexplored. Such investigations are critical to inform appropriately the treatment strategies for 
anovulation in PCOS.  
Polycystic ovarian morphology reflects aspects of disordered folliculogenesis in PCOS.47 
The morphological hallmark is an increased number of growing follicles, from the primary stage 
(0.06 mm) to the antral stage (2–5 mm). Histologic studies have confirmed that primary follicles 
are “stockpiled” in polycystic ovaries.55,54 Moreover, the total population of primary, secondary, 
and antral follicles is 2–3-fold greater in polycystic versus normal ovaries.53,55,54 This follicular 
excess is thought to reflect increased initiation of follicle growth from the primordial pool,54 slower 
maturation of primary follicles,55 and/or decreased follicle loss by atresia.56  
Despite the increased size of the growing pool, there is an apparent failure of normal 
selection and ovulation.47,46 Polycystic ovarian morphology is simultaneously characterized by a 
paucity of medium- and large follicles (>5 mm).57 Any large follicles present in the ovaries are 
presumably “arrested” in development due to impaired theca and granulosa cell function.47,46 
Namely, theca cells from polycystic ovaries have shown an enhanced capacity to produce 
androgens in response to luteinizing hormone (LH).49 Androgens may then promote theca and 
granulosa cell proliferation and stimulate excessive growth to the selectable stage (2–5 mm).47 
Further, granulosa cells from polycystic ovaries have shown premature responsiveness to LH in 
follicles as small as 4 mm. This implies the early acquisition of LH receptors, which in normal 
ovaries, does not occur until the time of selection (i.e. at ~10 mm).22,58 The theory is that these 
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functional abnormalities collectively result in an inhibition of terminal follicular growth at the 6–9 
mm stage.47,46 Androgens may further inhibit atresia after follicles stop growing and therefore 
contribute to a state of follicular “persistence.”59,60 
There is still a great deal to learn about disordered folliculogenesis in PCOS. First, it is not 
currently known whether antral follicle populations change over time or whether the follicular 
excess represents a constant phenomenon in PCOS. Second, it is not known whether the paucity 
of larger follicles in polycystic ovaries reflects follicle arrest or some other defect. Follicle arrest 
has never been observed in vivo, which is notable, because sporadic ovulation can occasionally 
occur and follicle growth can be stimulated by pharmacologic therapy.47,46 Third, it is not known 
whether follicles are protected from atresia in polycystic ovaries and whether they can “persist” at 
their maximum diameters for an extended period of time.59,60 Elucidating the defects that exist in 
PCOS is likely to improve treatment strategies for patients. This is particularly important in the 
context of assisted reproduction technologies, wherein women with PCOS have increased risk 
for ovarian hyperstimulation syndrome (OHSS) and often have resistance to first-line ovulation 
induction protocols (i.e. clomiphene citrate).5 
High-resolution transvaginal ultrasonography provides a non-invasive means to answer 
these questions, as it allows for the reliable detection of antral follicles ≥2 mm.39 Follicular growth, 
atresia, and ovulation have been serially evaluated in women with regular menstrual cycles.44,43,45 
and the established techniques can be readily applied to PCOS. Recent observations in our 
laboratory revealed substantial changes in follicle size populations on ultrasound scans performed 
one month apart in women with PCOS.64 These findings led to the notion that polycystic ovarian 
morphology may not solely represent a condition of follicular excess, arrest, and persistence. To 
that end, the objective of this study was to characterize follicle growth and turnover during an 
anovulatory interval in women with PCOS. We hypothesized that an active component of antral 
folliculogenesis would be captured on ultrasonography amidst follicular excess in this condition. 
5 
Based on our preliminary observations,64 we further hypothesized that frequent changes in the 
number and diameter of follicles would reflect follicular arrest, but not persistence.  
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METHODS 
 
Ethical Considerations 
Data from two separate, prospective, ongoing trials were evaluated in this study. Both 
research protocols were individually approved by the Institutional Review Board at Cornell 
University and the trials were registered at ClinicalTrials.gov (NCT01927432, NCT01785719). 
Informed consent was obtained from all participants before the study procedures were initiated.  
 
Study Participants 
One hundred twenty-eight women were recruited from the general population between 
2009 and 2016 (Figure 1.1). Paper and electronic advertisements were circulated throughout 
Cornell University and the surrounding Southern Tier Counties of New York State. Recruitment 
efforts were targeted to establish two distinct cohorts: (1) women with regular menstrual cycles 
(every 21–35 days) and (2) women with irregular menstrual cycles (>35 days apart). A major goal 
was to enroll an equal number of normal weight (body mass index, BMI, 18.5–24.9 kg/m2), 
overweight (BMI 25.0–29.9 kg/m2), and obese (BMI ≥30.0 kg/m2) women in each group. Potential 
participants were screened using general health and reproductive history, as well as physical and 
endocrine examination. Women of reproductive age (18–38 years), with consistent and optimal 
visualization of both ovaries on ultrasonography, were eligible to participate. Exclusion criteria 
were use of medications known or suspected to interfere with reproductive function in the two 
months prior to the study (e.g. hormonal contraception, fertility medications, antibiotics, antivirals); 
pregnancy or lactation in the six months prior to the study; history of premature ovarian failure or 
surgery; and preexisting medical conditions expected to interfere with study participation or 
outcomes (e.g. endometriosis, vaginal abnormalities, bleeding disorders, pre-diabetes, diabetes 
mellitus). Women with untreated thyroid abnormalities or hyperprolactinemia were excluded 
through appropriate hormone assessment, because these conditions mimic features of PCOS.7  
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Women who completed the study were retrospectively evaluated for inclusion in the 
present analysis (Figure 1.1). Cohorts of interest included: (1) overweight and obese women with 
anovulatory phenotypes of PCOS and (2) healthy controls. Anovulatory phenotypes of PCOS 
were identified based on the 2003 Rotterdam criteria.8,9 Oligo- or anovulation was judged by a 
self-reported history of irregular menstrual cycles (i.e. >35 days apart) and confirmed with 
ultrasound monitoring of ovarian follicular development during the study. To achieve the 
objectives of the present analysis, women with a pre-ovulatory follicle (>14 mm) or sporadic 
ovulation during the study were excluded (Figure 1.1). Hyperandrogenism was defined as a 
modified hirsutism score ≥7 or total testosterone concentration ≥65.4 ng/dL. These markers of 
androgen status were measured as described previously by our group,65 and internal thresholds 
were derived from the 95th percentiles of modified hirsutism scores and total testosterone 
concentrations in healthy women. Polycystic ovarian morphology was detected on transvaginal 
ultrasonography by a mean follicle number per ovary ≥25 or mean ovarian volume ≥10 mL.19,66 
Lean women (BMI 18.5–24.9 kg/m2) with PCOS were excluded from the present analysis, based 
on evidence that adiposity is involved in the mechanism of anovulation in PCOS46,67 and that 
reproductive dysfunction worsens at BMIs ≥25 kg/m2.68 Normal- and overweight (BMI <30 kg/m2) 
women with regular ovulatory cycles and normal androgen status were designated as Controls. 
Controls were matched for age, but not BMI, based on evidence that obesity (BMI ≥30 kg/m2) 
adversely affects ovulatory function (Figure 1.1.).69,70
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Figure 1.1.  Flow of participants through the observational cohort study (2009–2016) and present 
analysis. Shaded boxes designate the cohorts from which participants were selected for the 
present analysis. Abbreviations: PCOS, polycystic ovary syndrome; BMI, body mass index. 
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Ultrasonographic Measurements 
Serial transvaginal ultrasonography was used prospectively to evaluate antral follicle 
development (≥2 mm) in PCOS and Controls. Approaches were largely based on studies 
performed in healthy women by Baerwald and colleagues,44,71,72 but were modified where 
appropriate to evaluate outcomes in women with cycle irregularity. In women with PCOS, scans 
began at a random time and were performed every other day for 4–5 weeks. In Controls, scans 
were initiated in the mid-follicular phase and continued every other day for one inter-ovulatory 
interval (IOI). An IOI was defined as the time between consecutive ovulations and represented 
the luteal phase of one cycle followed by the follicular phase of the next cycle.44,72 This scanning 
regimen was necessary to capture the complete trajectory of follicular development, because 
ovulatory follicles can begin to grow as early as the luteal phase of the previous cycle.44,43 
Follicular growth was closely monitored in real-time in both groups. If a large follicle (≥14 mm) 
was detected, then ultrasound examinations were performed daily until its regression or ovulation. 
Ovulation was identified by subsequent observation of a corpus luteum.73,74 
Scans were performed by one of four operators using a GE Voluson E8 Expert System 
and 6–12 MHz 3D/4D transducer (GE Healthcare, Milwaukee, WI). Whole ovaries were imaged 
from their inner to outer margins in the longitudinal plane. Three-dimensional datasets were 
acquired using customized settings and the automated volume modality. Two-dimensional 
cineloops of each ovary in its sagittal and transverse planes were then extracted (Slice Thickness: 
0.5 mm) and archived for offline image analysis. Cineloops were evaluated by a single investigator 
with customized imaging software (Sante DICOM Editor, Santesoft LTD, Athens, Greece). Antral 
follicle number and diameter were assessed for each ovary and visit of the scanning interval. 
Reliable follicle counts were achieved with the grid system approach, as previously described by 
our group.75 Diameter measurements were obtained in the largest cross-sectional view of the 
follicle and calculated as the average of its two orthogonal dimensions (i.e. length × width). If a 
large follicle (≥10 mm) was detected, then the same measurements were repeated in a second 
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plane and the four dimensions were averaged. Mean follicle diameter was rounded to the nearest 
whole number.72 
Growth and regression profiles of individual follicles were assessed using the Identity 
Method.44,71,72 Briefly, the diameter and location of follicles that grew to ≥4 mm were sketched on 
paper for each ovary and visit of the scanning interval. Locations of individual follicles were 
designated by anatomical landmarks and positions relative to other follicles within the ovary and 
cineloop. Each follicle that grew to ≥7 mm was alphabetized (i.e. uniquely identified), and any 
changes in its diameter were tracked over time from day of first detection (at 4–5 mm) to day of 
last detection (at 4–5 mm).44,71,72  
Growth and regression rates of individual follicles were then determined. Sonographic 
presence was defined as the time between the first and last day of detection of a follicle.76 The 
growth phase of a follicle began on the day of first detection and ended on the day of maximal 
diameter.45 The regression phase of a follicle began on the day of maximal diameter and ended 
on the day of last detection.45,76 Static phases were identified when a follicle was detected within 
1 mm of its maximal diameter for at least three days (i.e. two visits).45,76 Data from the first and 
last day of a static phase coincided with the end of the growth phase and beginning of the 
regression phase, respectively, and were included in calculations of growth and regression 
rates.76 
Follicle number and diameter data were combined for both ovaries.44,72 The total number 
and proportion of follicles detected in different diameter categories were graphed for each woman 
over the scanning interval. Follicle populations of physiologic interest included: ≥2 mm, 2–9 mm, 
2–5 mm, 6–9 mm, and ≥10 mm. Diameter profiles of uniquely identified follicles were also graphed 
for each woman.  
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Biochemical Measurements 
Fasting blood samples were drawn on a single day of the study. Measurements were 
performed in the early follicular phase in Controls (i.e. days 1–8 of the menstrual cycle) or at a 
random time in women with PCOS. Time points were standardized in both groups such that no 
dominant follicles or active corpora lutea were present. Blood was collected into a clot-activated 
tube and allowed to sit at room temperature for 30–60 minutes. Serum was then isolated by 
centrifugation and stored at –80°C until analysis. Samples were shipped to an affiliate of the 
Centers for Disease Control and Prevention Hormone Standardization Program, and total 
testosterone was measured by liquid chromatography tandem mass spectrometry (Brigham 
Research Assay Core, Boston, MA). The inter-assay coefficient of variation was 6.4% and the 
measurement range was 1.00–2,000 ng/dl.77 Sex hormone binding globulin was measured in an 
aliquot of the same sample by chemiluminescence immunoassay (Immulite 2000; Siemens 
Medical Solutions Diagnostics, Deerfield, IL) at an internal clinical chemistry lab (Cornell 
University, Ithaca, NY). Intra- and inter-assay coefficients of variation were 3.1% and 5.1%, 
respectively. Free androgen index was calculated as: testosterone (nmol/l) / SHBG (nmol/l) × 100. 
 
Statistical Analysis 
Statistical analyses were performed with JMP Pro 12.0.1. (SAS Institute, Cary, NC, USA). 
The threshold for statistical significance was set at P≤0.05. Normality was determined visually 
with histograms or residual plots. Skewed data were evaluated after logarithmic transformation 
where appropriate.  
Demographic and diagnostic features were compared between groups using two-sample 
t-tests. Longitudinal profiles of follicle number and diameter were evaluated with combined and 
group-specific mixed models. Data were centralized to the day of the first study visit (PCOS) or 
ovulation (Control) and normalized over the mean scanning interval. Participant number was 
included as a random effect in each of the following models. Combined models were used to 
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assess between-group differences in the mean number of ≥2 mm, 2–9 mm, 2–5 mm, and 6–9 
mm follicles. In these models, PCOS diagnosis was designated as a categorical fixed effect. A 
“group” effect was interpreted as evidence of follicular excess in women with PCOS compared to 
Controls. Group-specific models were used to assess within-group changes in the mean number 
of ≥2 mm, 2–5 mm, and 6–9 mm follicles. In these models, time was designated as a continuous 
fixed effect (i.e. day of the scanning interval) and fit to a linear, quadratic, cubic, or quartic function 
where appropriate. Participant number, crossed with time, was added as a random effect. A “day” 
effect in the number of 2–5 mm or 6–9 mm follicles was interpreted as evidence of follicular 
recruitment during the scanning interval. In the event of a day effect in either follicle size 
population, additional models were conducted to clarify when recruitment had occurred. Time was 
designated as a categorical fixed effect (i.e. cycle phase). Anovulatory intervals were binned into 
three sequential 9–10-day intervals. IOIs were divided into the early follicular phase (with all 
follicles <10 mm), mid- to late-follicular phase (with evidence of at least one dominant or pre-
ovulatory follicle), and luteal phase (with evidence of a corpus luteum). A “phase” effect in the 
number of 2–5 mm or 6–9 mm follicles was then interpreted as evidence that recruitment had 
occurred during a specific phase. Mean follicle populations were compared between phases with 
post-hoc Tukey’s honest significant difference tests. The restricted maximum likelihood approach 
was used to identify the degree of intra-cycle versus inter-individual variation in each model. Last, 
combined models were used to assess between-group differences in the mean growth and 
regression profiles of uniquely identified follicles. As in the other combined models, PCOS 
diagnosis was designated as a categorical fixed effect. Follicle number, nested within participant 
number, was added as a random effect. A “group” effect in any growth-related endpoint was used 
to evaluate follicle arrest and turnover. 
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RESULTS 
 
Characteristics of Study Participants  
Study enrollment is described in Figure 1.1. Seventy-five women completed the study 
procedures. Twenty-two women represented the cohorts of interest and were included in the 
present analysis (n=11 women with PCOS, n=11 Controls) (Figure 1.1). General demographic 
and diagnostic features are compared between groups in Table 1.1. Women with PCOS differed 
from Controls across all features (P<0.05) except age (P=0.18) (Table 1.1).  
 
Table 1.1. Characteristics of study participants 
 PCOS (n = 11) Control (n = 11) 
Age (y) 26 ± 4 (21, 34)a 29 ± 6 (19, 38)a 
Body mass index (kg/m2) 36.3 ± 8.0 (26.4, 48.4)a 23.9 ± 1.9 (21.2, 27.3)b 
Menstrual cycle length (d) 197.3 ± 138.4 (50, 365)aǂ 29 ± 2 (24, 31)b 
Hirsutism score 8 ± 4 (1, 15)a 2 ± 3 (0, 6)b 
Total testosterone (ng/dL) 67.8 ± 27.9 (32.9, 118.0)a 30.5 ± 9.6 (17.6, 43.6)b 
Free androgen index 11 ± 6 (4, 23)a 2 ± 1 (1, 3)b  
Mean follicle number per ovary 50 ± 22 (14, 80)a 25 ± 9 (11, 35)b 
Mean ovarian volume (mL) 16 ± 4 (7, 21)a 6 ± 4 (2, 12)b 
Data are presented as mean ± SD (minimum, maximum). a,b Within rows, uncommon superscripts denote significant differences 
between groups, p<0.05.  Diagnostic endpoints were evaluated on a single day of the scanning interval and with respect to stage 
of cycle. ǂ Data related to menstrual cycle length were censored to the year prior to enrollment (i.e. 365 days). 
 
 
Women with PCOS were scanned for an average of 30 ± 3 days. Four women with PCOS 
reported amenorrhea and an absence of natural menstruation for at least one year prior to 
enrollment (Table 1.1: data were censored at 365 days). The remaining seven women reported 
oligomenorrhea with last menses having occurred between four and 60 days before the first 
study visit (mean ± SD: 25 ± 21 days). None of the women with PCOS showed ultrasonographic 
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evidence of recent ovulation during the scanning interval. Controls demonstrated normal IOI 
(mean ± SD: 28 ± 4 days), follicular-phase (mean ± SD: 17 ± 4 days), and luteal-phase lengths 
(mean ± SEM: 13 ± 1 days).44,78 Selection and ovulation of a dominant follicle was detected at 
least twice in each woman (i.e. at the beginning and end of the IOI).  
 
Evaluation of Follicular Excess 
Distributions of follicle populations for the entire scanning interval are presented in Figure 
1.2. In general, antral follicle counts ranged from 37 to 209 follicles in women with PCOS and 
from 15 to 85 follicles in Controls (Figure 1.2). Group-specific mixed models identified higher 
mean estimates for follicle number over time in women with PCOS (βIntercept: 105; SE: 12; 95% CI: 
78–133) compared to Controls (βIntercept: 49; SE: 4; 95% CI: 40–59). Combined analyses also 
revealed consistent evidence of follicular excess in PCOS. On any given day, more follicles (2–9 
mm) were detected in women with PCOS compared to Controls (βPCOS: 28; SE: 7; PPCOS<0.01; 
95% CI: 15–42). These differences were attributed to a greater number of both small (2–5 mm) 
(βPCOS: 25 (SE: 6); PPCOS<0.01; 95% CI: 13–38) and medium follicles (6–9 mm) (βPCOS: 3; SE: 1; 
PPCOS=0.02; 95% CI: 1–5) in PCOS.  
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Figure 1.2. Distributions of follicle number for the entire scanning interval in women with PCOS 
and controls. Box-and-whisker plots for the 2–9 mm, 2–5 mm, and 6–9 mm diameter categories 
are shown. The box represents the 25th and 75th percentiles and the horizontal line within the 
box represents the median. The 5th to 95th percentile range is reflected by the vertical bars. 
Outliers, if any, are denoted by dots. 
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Evaluation of Follicle Recruitment 
Mean profiles of follicle size populations are illustrated in Figure 1.3 and 1.4. Visually, 
antral follicle counts appeared constant over time in women with PCOS (Figure 1.3, A) and 
Controls (Figure 1.3, B). Group-specific models confirmed these observations. There was no 
effect of day on the number of follicles detected in either group (PCOS: PDay=0.23; Controls: 
PDay=0.98). 
Follicle diameter appeared constant over time in PCOS (Figure 1.4, A). In line with these 
observations, there was no effect of day on the number of small (PDay=0.20) or medium follicles 
(PDay=0.17) detected in this group. There was a small increase in the proportion of small follicles 
throughout the scanning interval (βDay: 0.25; SE: 0.10; PDay=0.01; 95% CI: 0.05–0.44), but there 
were no changes in the proportion of medium follicles (PDay=0.11). In PCOS, most of the variation 
in follicle populations was attributed to inter-individual differences (2–5 mm: 92%; 6–9mm: 75%), 
rather than intra-cycle fluctuation (2–5 mm: 8%; 6–9 mm: 25%). Collectively, these findings were 
not consistent with evidence of normal or excessive recruitment in women with PCOS.  
By contrast, follicle diameter appeared to fluctuate over time in Controls (Figure 1.4, B). 
Similar to previous reports,44,43 changes in diameter were non-random and dynamic. There was 
an effect of day on the number of both small (PDay<0.01) and medium follicles (PDay<0.01) in this 
group. The number of small follicles showed a significant peak in the luteal phase (LS Mean ± 
SE: 47 ± 4 follicles) and decreased by an average of 6 to 8 follicles during the early (PPhase<0.01) 
and mid-to-late follicular phases (PPhase<0.01). Concurrently, the number of medium follicles 
showed a significant nadir in the luteal phase (LS Mean ± SE: 4 ± 1 follicles) and increased by an 
average of 3 to 4 follicles during the early (PPhase<0.01) and mid-to-late follicular phases 
(PPhase<0.01) (Figure 1.4, B). Similar outcomes were observed in the proportions of small 
(PDay<0.01) and medium follicles (PDay<0.01). Unlike women with PCOS, variation in follicle 
populations was attributed to both intra- and inter-individual differences. Most of the variance in 
the models was attributed to both intra-cycle fluctuation (2–5 mm: 23%; 6–9 mm: 38%) and inter-
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individual differences (2–5 mm: 77%; 6–9 mm: 62%). Collectively, these findings were consistent 
with evidence of recruitment in the luteal phase and an active transition of follicles between 
physiologic cohorts preceding ovulation in Controls. 
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Figure 1.3. Mean profiles of antral follicle count during an anovulatory interval in women with 
PCOS (A) and an inter-ovulatory interval in controls (B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Profiles of physiologic cohorts (expressed as mean proportions of the antral follicle 
count) during an anovulatory interval in women with PCOS (A) and an inter-ovulatory interval in 
controls (B). Proportions of 2–5 mm (light gray), 6–9 mm (dark gray), and ≥10 mm (black) follicles 
are shown. Y-axes are truncated for better visibility of fluctuations over time. 
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Evaluation of Follicle Arrest and Turnover 
Follicles (n=501) that grew to ≥7 mm were uniquely identified and tracked over time. 
Despite significant differences in antral follicle counts between groups (Figure 1.2), there were no 
differences in the numbers of follicles that were tracked in women with PCOS (mean ± SD: 29 ± 
25 follicles) compared to Controls (mean ± SD: 16 ± 11 follicles) (P=0.24). On any given day of 
the scanning interval, the proportion of identified-to-total follicles was also similar between groups 
(PCOS versus Control, mean ± SD: 31 ± 29% versus 33 ± 17%; P=0.46).  
Representative plots of antral follicle development are provided for three women with 
PCOS and three Controls (Figure 1.5). Similar to previous reports,44,43 follicular growth appeared 
cyclic and organized in Controls, with distinct cohorts (or groups) of follicles developing at 1–3 
points during the IOI (Figure 1.5). Such patterns of growth and regression were not detected in 
women with PCOS.  
Rather, a spectrum of disordered antral follicle development was observed in PCOS 
(Figure 1.5). At the mild end of the spectrum, fewer than 10% of follicles grew to ≥7 mm. The 
growth and regression of at least one distinct follicular cohort was detected during the scanning 
interval (represented by Subject 019). In the middle of the spectrum, between 10 and 30% of 
follicles grew to ≥7 mm. The growth and regression of at least three follicular cohorts was 
detected. Yet, unlike the mild group, some growth profiles overlapped with one another and 
cohorts were more difficult to distinguish (represented by Subject 018). Last, at the severe end of 
the spectrum, more than 40% of follicles grew to ≥7 mm. Multiple follicles emerged and regressed 
at different times during the scanning interval. All growth profiles overlapped with one another, 
and individual cohorts were impossible to resolve (represented by Subject 107). Across the 
spectrum, however, there was subjective evidence of more frequent follicular turnover in PCOS 
(Figure 1.5). 
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Figure 1.5. Representative profiles of follicle growth and antral follicle count during an anovulatory 
interval in women with PCOS (left) and an inter-ovulatory interval in controls (right). Each uniquely 
identified follicle is represented by a different gray line. Note that all follicles that grew to ≥7 mm 
could be individually tracked over time using the Identity Method. Asterisks indicate ovulatory 
follicles. The antral follicle count is represented by a black line.  
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Complete growth and regression profiles (from first to last day of detection) were available 
for 177 follicles in women with PCOS and 121 follicles in Controls. Growth and regression 
parameters are presented in Table 1.2. Follicles grew to smaller maximum diameters in women 
with PCOS compared to controls (P<0.01). These findings reflected differences in ovulatory status 
between groups and provided ultrasonographic evidence of follicular arrest in PCOS. Follicles 
were also detected for a shorter interval in women with PCOS (P<0.01), which reflected shorter 
growth phases (P<0.01), and similar static (P=0.87) and regression phases (P=0.07). Growth 
(P=0.11) and regression rates (P=0.85) were similar between groups. These findings were not 
consistent with the notion of follicular persistence in PCOS (Table 1.2). 
 
Table 1.2. Growth parameters of identified follicles 
 PCOS (n = 11)ǂ Control (n = 11)ǂ 
Sonographic presence (d) 9.9 ± 0.5 (8.8, 10.9)a 12.2 ± 0.5 (11.2, 13.3)b 
Growth phase (d) 3.9 ± 0.2 (3.4, 4.4)a 5.7 ± 0.2 (5.2, 6.2)b 
Growth rate (mm/d) 0.62 ± 0.02 (0.56, 0.67)a 0.67 ± 0.02 (0.62, 0.72)a 
Static phase (d) 3.6 ± 0.4 (2.7, 4.4)a 3.7 ± 0.4 (2.8, 4.5)a 
Maximum diameter (mm) 7.2 ± 0.2 (6.7, 7.7)a 8.6 ± 0.2 (8.1, 9.1)b 
Regression phase (d)  4.2 ± 0.3 (3.6, 4.7)a 4.9 ± 0.3 (4.3, 5.5)a 
Regression rate (mm/d) –0.57 ± 0.03 (–0.63, –0.52)a –0.57 ± 0.03 (–0.63, –0.51)a 
Data are presented as LS Means ± SE (95% CI). a,b Within rows, uncommon superscripts denote a significant effect of PCOS, 
p<0.05. ǂ Models included data from 177 follicles in women with PCOS and 121 follicles in Controls. 
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DISCUSSION 
 The objective of the present study was to characterize antral follicle growth and turnover 
in women with PCOS. For the first time, we have documented that follicular excess is constant 
during an anovulatory interval and cannot be explained by normal or increased recruitment. In 
addition, we have also revealed that follicles in polycystic ovaries become arrested at the mid-
antral stage and undergo more frequent turnover than follicles in healthy ovaries. This new 
knowledge challenges the traditional theory of follicular persistence in PCOS.  
The excess of small, medium, and total antral follicles has long been considered a salient 
feature in PCOS. This observation is consistent in vitro studies, which have confirmed that 
polycystic ovaries contain substantially more follicles than normal ovaries.53,55,54 Our study 
extends these data to support that follicular excess is also a constant feature over time. The 
demonstration of non-significant intra-cycle variation in antral follicle counts in PCOS may have 
important implications for the diagnosis of this condition. Currently, diagnostic evaluations of 
polycystic ovaries are restricted to the early follicular phase of a natural cycle or 
pharmacologically-induced withdrawal bleed. This greatly limits the timing to confirm a diagnosis 
of PCOS and places an additional burden on patients, when menstrual cycle status is uncertain, 
and medications are needed to immediately control symptomology. Our findings suggest that it 
may be appropriate to evaluate polycystic ovarian morphology at random times.19,20 A more direct 
assessment is needed to confirm this theory. Non-significant intra-cycle variation was also 
observed in antral follicle counts in our Control cohort. This finding is not consistent with previous 
evaluations of follicle number during regular menstrual cycles.79,80 Differences in our study may 
relate to our use of updated imaging technology19 and reliable techniques to detect smaller 
follicles in the ovaries.75 Yet, we postulate that even significant intra-cycle variation would not 
confound the potential of the current sonographic definition of polycystic ovarian morphology to 
detect PCOS.66 
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 We did not find evidence of excessive follicular recruitment in women with PCOS. It has 
been hypothesized that the accumulation of follicles in polycystic ovaries reflects the increased 
growth of follicles to the small antral stage (2–5 mm). Androgens presumably modulate this 
process.47 We, therefore, expected to observe frequent changes in the number of 2–5 mm follicles 
throughout the anovulatory interval. Although some fluctuation was noted at the individual level, 
a day effect was not detected for this follicle size population at the group level. The absence of a 
day effect in the small follicles may have reflected the approach we used to standardize the data 
over the anovulatory interval. Because it is often difficult to predict menses in women with PCOS, 
our participants began the study at a random time. Self-reported last menses had occurred 
anywhere from four to >365 days prior to the first study visit. It is unknown whether follicular 
development differs in oligo- versus anovulatory women. Such differences may have impacted 
our ability to detect changes in follicle populations, because “time” was standardized to an 
arbitrary visit rather than cycle day. We attempted to reconcile this issue by standardizing our 
data based on the timing of distinct increases in the number of medium-sized follicles in each 
woman. This approach has been used to align follicular events during regular ovulatory cycles.44 
Yet, surprisingly, when we standardized the data to these time points, we still could not identify 
changes in follicle populations over time in PCOS (data not shown). The observation that antral 
follicle development occurred along a spectrum of disorder supports the notion that 
standardization to distinct time points in antral folliculogenesis may not be possible in PCOS. 
Future studies may require the identification and use of new methods that can better characterize 
the spectrum of disordered folliculogenesis in this condition. 
 We also did not find evidence of normal follicular recruitment in women with PCOS. 
Controls exhibited an increase in the number of 2–5 mm follicles in the luteal phase, which was 
consistent with the single recruitment of a follicular cohort.35 We subsequently observed a 
transition of follicles between diameter categories, as judged by changes in the numbers and 
proportions of small and medium follicles. Previous studies have shown that this transition reflects 
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multiple “waves” of follicular development during an IOI and culminates in the selection and 
ovulation of a dominant follicle.44,43 Intra-cycle fluctuation in the small and medium follicles was 
substantial and significant in Controls (i.e. >20%). But, in women with PCOS, we suspect that the 
absence of similar fluctuation or transition reflects the known impairments in gonadotropin 
signaling in this condition.47,46,25 
 Our findings represent the first in vivo evidence of follicular arrest in PCOS. Previously, 
histologic studies have suggested that follicles in polycystic ovaries can acquire LH receptors at 
diameters of 8 mm or smaller. This results in premature terminal differentiation of the granulosa 
cells and halts follicular development beyond the 6–9 mm range.58 Consistent with these data, we 
noted that follicles in polycystic ovaries stopped growing at a diameter of 7 mm. Some follicles 
reached the 9 or 10 mm stage, but this was not a universal finding among women with PCOS. 
Growth rates of follicles to their maximum diameters did not differ between women with PCOS 
and Controls. Comparative data are only available for women with regular menstrual cycles.45 In 
a recent study performed by Baerwald and colleagues, the mean follicular growth rate during 
natural cycles was 50% higher than in our Control cohort (1.42 versus 0.67 mm/day).45 This may 
reflect our less frequent scanning regimen or revised methods for tracking follicles and defining 
static phases.45  
 Our findings also represent the first in vivo evidence that follicular persistence does not 
occur at the antral stages of development in PCOS. We noted that follicles in polycystic ovaries 
demonstrate similar regression phases and rates to follicles in normal ovaries. This was an 
unexpected finding, given that decreased atresia has been implicated in the mechanism of 
follicular excess. The intra-ovarian and systemic factors involved in increased follicular turnover 
in PCOS are unknown. Importantly, these findings do not exclude the possibility that pre-/small 
antral follicles (rather than medium follicles) are still protected from atresia by androgens.60,56 Our 
data were derived from the Identity Method, which enables an evaluation of larger follicles (>6 
mm) in the ovaries. We were able to uniquely identify and track the development of ~30% of 
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follicles in both the PCOS and Control groups. However, the abundance of antral follicles in 
polycystic ovaries made it challenging to characterize follicular dynamics in the 2–5 mm range. It 
is, therefore, possible that we did not capture the complete picture of antral development in PCOS.  
We noted a spectrum of disordered follicle development in women with PCOS. This is not 
surprising given the heterogeneity of the condition itself. Endocrine and metabolic features can 
vary substantially among patients and exist on a spectrum from mild to severe.51 Because normal 
ovarian follicular development is regulated by systemic mechanisms,22 it is possible that variations 
in follicle growth reflect variations in biochemical factors among women. This is in line with clinical 
evidence from pharmacologic interventions for anovulation, which have documented increased 
risk for OHSS in women with higher antral follicle counts.81 If follicles can be “rescued” from arrest 
by administration of exogenous follicle-stimulating hormone,47 then we hypothesize that OHSS 
may be more likely in women with a greater proportion of growing follicles (i.e. more severe 
disorder). Likewise, restored ovulatory cyclicity after dietary intervention82 may be more likely in 
women with a smaller proportion of growing follicles (i.e. less severe disorder). These hypotheses 
merit further investigation. 
There were three major limitations to our study. First, cohorts of interest were carefully 
selected by BMI. We focused on overweight and obese women with PCOS, because adiposity 
has been implicated in the mechanism of anovulation in this condition.47,46,67 Most patients are 
also overweight and consequently experience greater severity of reproductive dysfunction than 
their normal-weight counterparts.61,68 However, it is important to acknowledge that adiposity can 
adversely impact the menstrual cycle in otherwise healthy women.83,84 Additional studies are 
needed to determine whether aspects of antral folliculogenesis differ between normal- and 
overweight women with PCOS. Second, we relied on the broadest diagnostic criteria to define 
PCOS. While these Rotterdam criteria are recommended in clinical practice and research,6 they 
also recognize a controversial normoandrogenic anovulatory phenotype.14,15 Women with “Mild 
PCOS” experience less severe reproductive disturbances11 and are more likely to respond to 
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some ovulation induction therapies than their hyperandrogenic counterparts.85 Our study largely 
included women with Frank PCOS (i.e. oligo- or anovulation, hyperandrogenism, and polycystic 
ovarian morphology). However, two of the women had Mild PCOS (i.e. oligo- or anovulation, 
normal androgens, and polycystic ovarian morphology). Further studies are needed to evaluate 
antral folliculogenesis in normo- versus hyperandrogenic women. Finally, our study was limited 
by the absence of concurrent serial endocrine evaluation. Pituitary gonadotropin and ovarian 
steroid hormone profiles over the anovulatory interval would greatly inform the etiology of follicular 
emergence and turnover in PCOS. These assessments would also help to elucidate the 
mechanisms that regulate follicular growth and the spectrum of disordered folliculogenesis 
observed in our participants.  
 In summary, the observation of frequent follicular turnover in polycystic ovaries provides 
a new model for antral folliculogenesis in PCOS. We anticipate that knowledge of a spectrum of 
disordered follicle growth will have profound implications for the treatment of infertility in this 
condition. In particular, it may help us to understand differences in the ovulatory response to 
lifestyle82 or pharmacologic interventions.5 Consideration of these findings may also enable the 
identification of better predictive markers of response to these therapies in PCOS, which are 
necessary to guide treatment strategies and provide patients with realistic expectations for 
treatment outcomes. 
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CHAPTER 2 
SONOGRAPHIC EVALUATION OF SPORADIC OVULATORY CYCLES  
IN OLIGOMENORRHEIC WOMEN WITH POLYCYSTIC OVARY SYNDROME 
 
ABSTRACT 
 
Objectives. The extent to which antral follicle development is impaired in polycystic ovary 
syndrome (PCOS) is unknown. Although anovulation is a common outcome, some follicles in 
polycystic ovaries can occasionally progress to dominance and ovulate during natural cycles. 
Factors associated with the sporadic emergence of an ovulatory follicle have never been 
described in PCOS, largely because it is challenging to predict such an event in women with 
menstrual irregularity. By chance, we observed an ovulation in a subgroup of women with 
anovulatory phenotypes of PCOS. The objectives of the present analysis were to evaluate the 
growth kinetics of ovulatory follicles and identify the clinical factors associated with sporadic 
ovulation in PCOS.  
 
Methods. Women with PCOS (n = 24) and Controls (n = 11) were evaluated by serial ovarian 
ultrasonography for 4–5 weeks. Endocrine and metabolic tests were performed on a single day 
during the early follicular phase. Women with PCOS were divided into two groups based on 
sonographic evidence of anovulation (PCOS-Anov) or sporadic ovulation (PCOS-Ov). Unique 
growth profiles of ovulatory follicles were assessed using offline image analysis, and the Identity 
Method. Diagnostic, morphologic, endocrine, and metabolic features were compared between 
PCOS-Anov, PCOS-Ov, and Control groups using t-tests or one-way ANOVA. 
 
Results. Half of women with PCOS exhibited sporadic ovulation during the study. On average, 
ovulatory follicles were selected after shorter growth phases (6 vs. 8 days; P<0.01) and at smaller 
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diameters (8 vs. 10 mm; P=0.04) in the PCOS-Ov versus Control group. Women with PCOS-Ov 
were distinguished from their anovulatory counterparts by shorter cycle lengths (75 vs. 197 days; 
P=0.01), lower total testosterone concentrations (44.6 vs. 67.8 ng/dl; P=0.04), and lower free 
androgen indices (6 vs. 11; P=0.01). Women with PCOS-Ov had similar antral follicle counts, 
ovarian volumes, waist circumferences, and waist-to-hip ratios to both women with PCOS-Anov 
and Controls. 
 
Conclusions. Ovulatory follicle growth kinetics are altered in women with PCOS. The implications 
of early follicular selection for oocyte quality, luteal function, and fertility/fecundity are unclear. 
Likelihood of sporadic ovulation may be linked to the severity of reproductive and endocrine 
disturbances in women with PCOS.
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INTRODUCTION 
Ovulatory dysfunction in polycystic ovary syndrome (PCOS) is characterized by the arrest 
of ovarian follicle development at the mid-antral stage.47,46 Systemic endocrine and metabolic 
abnormalities presumably converge at the ovary58,63,49,86 and interfere with the cyclic processes of 
selection and ovulation.46 However, follicular arrest may not provide a complete explanation for 
the disordered folliculogenesis and anovulation in PCOS.47,46 Namely, not all follicles in polycystic 
ovaries show abnormal function58 and some are able to advance periodically towards ovulation.87 
The notion that a dominant follicle can “escape” from any systemic or intraovarian inhibition during 
natural cycles has never been prospectively explored in PCOS.  
 Oligo-ovulatory women with PCOS consistently demonstrate abnormal endocrine profiles, 
including elevated serum concentrations of luteinizing hormone (LH) and androgens, and reduced 
serum concentrations of follicle-stimulating hormone (FSH).51,52 These profiles arise from 
disruptions across the hypothalamic-pituitary-ovarian axis. Pulsatile secretion of gonadotropin-
releasing hormone from the hypothalamus is persistent and rapid in PCOS. This pattern favors 
the synthesis of LH by the anterior pituitary and contributes to an increased LH: FSH ratio.48 High 
levels of LH49 and increased activity of steroidogenic enzymes50 augment ovarian androgen 
production in polycystic ovaries. Androgens may then stimulate excessive follicular growth to the 
selectable stage (2–5 mm),57 while low levels of FSH inhibit further follicle maturation and 
contribute to reduced serum concentrations of estradiol.47,46 Together, milder disruptions in the 
endocrine environment (lower LH, lower androgens, and higher FSH) could enable dominant 
follicle development in PCOS.88 
Metabolic abnormalities are also common in women with PCOS.89 Worldwide, more than 
half of patients are overweight or obese.61 and roughly two-thirds of women demonstrate insulin 
resistance.90 Adiposity-induced hyperinsulinemia is intimately involved with the mechanism of 
anovulation in PCOS.47,46 Insulin can act on polycystic ovaries91 to amplify ovarian androgen 
production92 and increase the response of granulosa cells to LH63 Consequently, granulosa cells 
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from small- and medium-sized antral follicles (4–8 mm) are able to respond to LH.58 This implies 
an early acquisition of LH receptors, which in normal ovaries does not occur until the time of 
selection at ~10 mm.22,58 Premature exposure of granulosa cells to LH is believed to inhibit further 
follicular maturation and prevent growth beyond 8–10 mm.58 As such, improved metabolic status 
(lower insulin levels and better insulin sensitivity) could also promote dominant follicle 
development in PCOS.64 
 The factors associated with sporadic ovulation in this population are ultimately unknown. 
We recently performed a prospective evaluation of antral follicle development during natural 
cycles in PCOS (Chapter 1). Based on their histories of oligo- or amenorrhea, we expected that 
85–100% of women with PCOS would remain anovulatory during study.64 However, a substantial 
proportion exhibited sonographic evidence of sporadic ovulation. These serendipitous findings 
provided a rare opportunity to gain insight into the mechanism(s) of natural ovulation in PCOS. 
To that end, the objective of the present study was to evaluate follicular, endocrine, and metabolic 
features during sporadic ovulatory cycles in PCOS. Given the demonstration that antral follicle 
function58 and growth dynamics (Chapter 1) are altered in PCOS, we hypothesized that 
differences in ovulatory follicle growth would also be observed in women with PCOS compared 
to regular ovulatory cycles. We further hypothesized that milder endocrine and metabolic 
abnormalities would be detected in women that experienced sporadic ovulation versus those that 
remained anovulatory during the study. 
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METHODS 
 
Ethical Considerations 
Data from two separate, prospective, ongoing clinical trials were evaluated in this study 
(ClinicalTrials.gov Identifiers: NCT01927432, NCT01785719). Both research protocols were 
approved by the Institutional Review Board at Cornell University, and informed consent was 
obtained from all participants before study procedures were initiated.  
 
Study Participants 
Seventy-five women completed the study procedures (Chapter 1 and Figure 2.1). Women 
of reproductive age (18–38 years) were recruited through public advertisement. Exclusion criteria 
included the use of confounding medications in the preceding two months (e.g. hormonal 
contraception, fertility medications, antibiotics, antivirals), recent pregnancy or lactation, history 
of premature ovarian failure or surgery, and concurrent endocrine disease(s) or disorder(s) 
besides PCOS (e.g. thyroid abnormalities, hyperprolactinemia, pre-diabetes, diabetes mellitus). 
Women were evaluated for inclusion in the present analysis based on PCOS diagnosis, body 
mass index (BMI), and observations made during the study (Figure 2.1). Cohorts of interest 
included: (1) overweight / obese women with anovulatory phenotypes of PCOS (BMI ≥25.0 kg/m2) 
and (2) normal- / overweight (BMI 18.5–29.9 kg/m2) women with regular ovulatory cycles (Control) 
(Chapter 1). Women with PCOS were further stratified based on ultrasonographic evidence of 
anovulation (PCOS-Anov) or sporadic ovulation (PCOS-Ov) during the study (Figure 2.1). PCOS 
was diagnosed according to the Rotterdam criteria,8,9,19 as previously described (Chapter 1). By 
definition, all women in the PCOS-Anov and PCOS-Ov groups were oligo- or anovulatory at the 
time of enrollment, based on self-report of amenorrhea (no bleeding for the past 3 months) or 
oligomenorrhea (fewer than 10 periods in the past year).  
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Figure 2.1. Flow of participants through the observational cohort study (2009–2016) and present 
analysis. Shaded boxes designate the cohorts from which participants were selected for the 
present analysis. Abbreviations: PCOS, polycystic ovary syndrome; BMI, body mass index. 
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Study Design 
The study was conducted over a period of 4–6 weeks. Participants visited the research 
unit every other day during the study. At each visit, transvaginal ultrasonography of the ovaries 
was performed to evaluate follicle growth (Chapter 1). Women underwent additional clinical and 
biochemical assessments at one of the visits to measure endocrine and metabolic status. Details 
of ultrasonographic, clinical, and biochemical assessments are provided below. 
 
Ultrasonographic Measurements 
Ultrasound scanning regimens differed between groups. In women with PCOS, scans 
were initiated at a random time and continued every other day for the duration of the study. In 
Controls, scans began on days 8–14 after menses and were performed every other day for one 
inter-ovulatory interval (IOI). An IOI was defined as the time between consecutive ovulations.44,72 
Follicular growth was closely monitored in real-time. If a large follicle (≥14 mm) was detected, 
then ultrasound examinations were performed every day until its regression or ovulation. 
Ovulation was defined by disappearance of the large follicle and subsequent formation of a corpus 
luteum.73,74 Anovulation was defined by an absence of follicle growth >10 mm. Ovarian data were 
acquired with a high-resolution ultrasound machine and 6–12 MHz endovaginal transducer (GE 
Voluson E8 Expert System, GE Healthcare, Milwaukee, WI). Whole ovaries were imaged from 
their inner to outer margins in the longitudinal plane, and digital cineloops were recorded for offline 
analysis (Santesoft DICOM Editor, Santesoft LTD, Athens, Greece).  
Follicles were counted and measured in each cineloop using the grid system approach.75 
Data from the left and right ovaries were combined. The numbers of follicles detected across the 
scanning interval were then binned into five diameter categories: ≥2 mm, 2–9 mm, 2–5 mm, 6–9 
mm, and ≥10 mm. Mean ovarian volume was also calculated at each visit using the formula for a 
prolate ellipsoid.20,93,94  
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Methods used for tracking follicle diameter over time were performed as described in 
Chapter 1. In the present analysis, growth trajectories of ovulatory follicles were characterized 
from emergence to ovulation. Day of emergence was defined as the day on which the ovulatory 
follicle was first detected, retrospectively, at 4–5 mm.43 Day of selection was defined as the day 
immediately preceding a difference in growth trajectories between the ovulatory follicle and other 
follicles present in the ovaries. Specifically, the ovulatory follicle continued to grow, while the next 
largest follicle(s) began a static or regression phase.72 An ovulatory follicle was considered 
dominant when it grew to ≥10 mm and exceeded the diameters of other follicle(s) by at least 2 
mm.43 The interval of time and growth rate of the ovulatory follicle between each event was 
determined (Chapter 1).  
 
Clinical and Biochemical Measurements 
 The following procedures were conducted in the morning after an overnight fast: (1) 
hirsutism assessment, (2) anthropometry, (3) dual x-ray absorptiometry, (4) venipuncture, and (5) 
2-hour 75-gram oral glucose tolerance test. In both the PCOS and Control groups, tests were 
standardized to the early follicular phase, on a day when no dominant follicles or active corpora 
lutea were present. Male-patterned hair growth was evaluated using the modified Ferriman-
Gallwey scoring system95, as previously described65. Anthropometry was performed to assess 
height, weight, and waist circumference. Participants were weighed with light clothes and no 
shoes on a standard digital scale; BMI was calculated as weight (kilograms) divided by squared 
height (meters). Waist circumference was measured with soft tape at the midpoint between the 
lowest rib and iliac crest. Dual x-ray absorptiometry (Discovery-A, Hologic, Inc., Bedford, MA) was 
performed to assess total and abdominal body fat. Total fat was determined by measurement of 
fat versus lean mass in soft tissue, and abdominal fat was distinguished as the region between 
the ribs and iliac crests.   
35 
Fasting concentrations of total testosterone and sex hormone binding globulin (SHBG) 
were measured, as previously described (Chapter 1). The free androgen index was calculated 
(testosterone / SHBG × 100) and used as a surrogate estimate of free testosterone. Serum 
concentrations of FSH, LH, and estradiol were measured by chemiluminescent immunoassay 
(Immulite 2000; Siemens Medical Solutions Diagnostics, Deerfield, IL). Intra- and inter-assay 
coefficients of variation were as follows: FSH and LH (3.4%, 5.4%), and estradiol (6.7%, 9.7%). 
Glucose and insulin concentrations were assessed at 0, 30, 60, 90, and 120 minutes of the oral 
glucose tolerance test. Venous glucose was immediately quantified with a glucometer (Accu-
Check® Aviva, Roche Diabetes Care, Inc., Indianapolis, IN). Serum was isolated from whole 
blood (Chapter 1). Insulin was measured by chemiluminescent immunoassay (Immulite 2000; 
Siemens Medical Solutions Diagnostics, Deerfield, IL). Intra- and inter-assay coefficients of 
variation for insulin were 4.8% and 6.2%, respectively. The homeostatic model assessment of 
insulin resistance (HOMA) and whole-body insulin sensitivity index (WBISI) were calculated as 
surrogate markers of insulin sensitivity.96 
 
Statistical Analysis 
Statistical analyses were performed with JMP Pro 12.0.1. (SAS Institute, Cary, NC, USA). 
The threshold for significance was set at P≤0.05. Profiles of follicle number and diameter were 
centralized to the day of the first study visit (PCOS) or ovulation (Control), and data were averaged 
over the entire scanning interval. Normality was assessed visually with histograms and skewed 
data were log-transformed for between-group comparisons where appropriate. Women with 
PCOS were considered as a combined cohort (“PCOS”) and as two separate groups (“PCOS-
Anov” and “PCOS-Ov”). Differences between groups were evaluated by two-sample t-tests or 
one-way ANOVA with post-hoc Tukey’s HSD tests. One subject was taking an insulin-sensitizing 
medication during the study. The medication had been prescribed for PCOS; she did not have 
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pre-diabetes or diabetes mellitus. Sensitivity analyses confirmed that her inclusion in the dataset 
did not have any impact on the results.
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RESULTS 
 
Characteristics of Study Participants 
Study enrollment is described in Figure 2.1. Complete datasets were available for 26 
overweight and obese women with anovulatory phenotypes of PCOS. Eleven of the 26 women 
with PCOS (42%) exhibited anovulation (PCOS-Anov) during the study and 13 (50%) showed 
sonographic evidence of sporadic ovulation (PCOS-Ov). Dominant follicles (≥14 mm) were 
detected in two additional women (8%), but the study ended before their fates could be 
determined. Therefore, both women were excluded from the present analysis. Results are 
presented for 24 overweight or obese women with PCOS and 11 non-obese women with regular 
ovulatory cycles. Diagnostic features are compared between PCOS and Controls in Table 2.1. 
 
Table 2.1. Characteristics of study participants 
 PCOS (n = 24) Control (n = 11) 
Age (y) 28 ± 5 (21, 36)a 29 ± 6 (19, 38)a 
Body mass index (kg/m2) 35.5 ± 7.0 (25.7, 48.4)a 23.9 ± 1.9 (21.2, 27.3)b 
Menstrual cycle length (d) 136 ± 118 (41, 365)aǂ 29 ± 2 (24, 31)b 
Hirsutism score 7 ± 4 (1, 15)a 2 ± 3 (0, 6)b 
Total testosterone (ng/dL) 55.7 ± 26.7 (15.8, 118.0)a 30.5 ± 9.6 (17.6, 43.6)b 
Free androgen index 8 ± 5 (1, 23)a 2 ± 1 (1, 3)b 
Mean follicle number per ovary 43 ± 21 (14, 84)a 26 ± 7 (15, 36)b 
Mean ovarian volume (mL) 14 ± 5 (7, 21)a 6 ± 4 (2, 12)b 
Data are presented as mean ± SD (minimum, maximum). a,b Within rows, uncommon superscripts denote significant differences 
between groups determined by t-test, p<0.05. Diagnostic endpoints were evaluated on a single day of the scanning interval and 
with respect to stage of cycle. ǂ Data related to menstrual cycle length were censored to the year prior to enrollment (i.e. 365 days). 
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Observation of Sporadic Ovulation 
Women with PCOS (n=24) reported having a maximum of nine periods in the year prior to 
enrollment (Table 2.1). Last menses had occurred approximately two months before the first study 
visit (mean ± SD: 54 ± 80 days; range: 4 to >365 days). Representative plots of follicle growth 
during the scanning interval are illustrated for the PCOS-Anov, PCOS-Ov, and Control groups in 
Figure 2.2.  
Women with PCOS-Anov (n=11) were evaluated for a mean of 30 ± 5 days. Follicular 
growth did not exceed 10 mm at any time during the scanning interval (Figure 2.2, A–B). The 
majority of uniquely identified follicles developed to a mean diameter of 7.2 ± 0.2 mm before 
undergoing atresia (Chapter 1; Figure 2.2, A). Three of the 11 women with PCOS-Anov showed 
evidence of dominance despite anovulation. Each dominant follicle (n=3/3) emerged at the 4–5 
mm stage, developed to a maximum diameter of 10 mm, and then regressed 1–2 days later 
(Figure 2.2, B). 
Women with PCOS-Ov (n=13) were evaluated for a mean of 31 ± 5 days. Ovulation was 
observed once in each participant (Figure 2.2, C–D). Ovulatory follicles either emerged before 
the first study visit (n=4/13; Figure 2.2, C) or between the first and third weeks of the scanning 
interval (n=9/13; Figure 2.2, D). Ovulatory follicles that emerged before the first study visit were 
tracked from selection (n=3/13) or pre-ovulatory diameters (n=1/13) to ovulation (Figure 2.2, C). 
Ovulatory follicles that emerged between the first and third weeks of the scanning interval were 
tracked from emergence to ovulation (n=9/13; Figure 2.2, D). Consistent with the criteria for oligo- 
or amenorrhea, mean follicular phase length from self-reported last menses to ovulation was 56 
± 45 days (PCOS-Ov, n=13). A complete luteal phase was documented in 11 of 13 women (mean 
luteal phase length ± SD: 12 ± 2 days). The remaining two women left the study after ovulation 
had been observed, but before the subsequent menses began. 
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Figure 2.2. Representative plots of follicle growth during the scanning interval from women in the 
PCOS-Anov (n = 2; A–B), PCOS-Ov (n = 2; C–D), Control (n = 2; E–F) groups. Each uniquely 
identified follicle (that grew to ≥7 mm) is represented by a different gray line. Asterisks indicate 
the ovulatory follicles. Abbreviations: FP, follicular phase; LP, luteal phase; M, menses.  
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Follicle Growth 
 Growth kinetics of ovulatory follicles are compared between the PCOS-Ov and Control 
groups in Table 2.2. Overall, the mean growth phase (P=0.90) and growth rate (P=0.98) of 
ovulatory follicles from emergence to ovulation did not differ in women with PCOS-Ov versus 
Controls. However, differences were noted between the two groups before and after selection. 
The mean interval from emergence to selection was shorter in women with PCOS-Ov than in 
controls (P<0.01). This resulted in a smaller mean diameter on the day of selection in the PCOS-
Ov group (8 versus 10 mm, respectively; P=0.04). Conversely, the mean interval from selection 
to ovulation was longer in women with PCOS-Ov than in Controls (P<0.01). This resulted in a 
slightly larger maximum pre-ovulatory diameter in the PCOS-Ov group (20 versus 19 mm; 
P=0.09). Luteal phase lengths did not differ between groups (P=0.38) (Table 2.2).  
 
Table 2.2. Growth characteristics of ovulatory follicles in the PCOS-Ov and Control groups 
 PCOS-Ov (n = 13) Control (n = 11) 
Emergence to ovulation   
     Growth phase (d) 14 ± 3 (11, 20)a 14 ± 2 (8, 17)a 
     Growth rate (mm/d) 1.10 ± 0.27 (0.85, 1.64)a 1.10 ± 0.20 (0.82, 1.50)a 
Emergence to selection 
     Growth phase (d) 6 ± 2 (3, 7)a 8 ± 2 (5, 13)b 
     Growth rate (mm/d) 0.66 ± 0.19 (0.40, 1.00)a 0.73 ± 0.21 (0.50, 1.11)a 
     Diameter at selection (mm) 8 ± 1 (7, 10)a 10 ± 2 (7, 14)b 
Selection to ovulation   
     Growth phase (d) 10 ± 3 (5, 17)a 7 ± 2 (3, 10)b 
     Growth rate (mm/d) 1.25 ± 0.30 (0.82, 1.78)a 1.39 ± 0.34 (1.00, 2.25)a 
     Maximum diameter (mm) 20 ± 2 (16, 23)a 19 ± 2 (16, 23)a 
Luteal phase length (d) 12 ± 2 (7, 15)a 13 ± 1 (11, 15)a 
Data are presented as mean ± SD (minimum, maximum). a,b Within rows, uncommon superscripts denote significant differences 
between groups determined by t-test, p<0.05. Each woman contributed data from a single ovulatory follicle. 
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Between-Group Differences in Diagnostic Features 
 Diagnostic features are compared among the PCOS-Anov, PCOS-Ov, and Control groups 
in Table 2.3. By design, women with PCOS differed from Controls by longer menstrual cycles 
(PCOS-Anov: P<0.01; PCOS-Ov: P=0.01), higher hirsutism scores (PCOS-Anov: P<0.01; PCOS-
Ov: P=0.03), higher free androgen indices (PCOS-Anov: P<0.01; PCOS-Ov: P<0.01), and larger 
ovarian volumes (PCOS-Anov: P<0.01; PCOS-Ov: P<0.01). Women with PCOS-Anov were 
further distinguished from Controls by higher total testosterone concentrations (P<0.01) and 
higher mean follicle counts (P=0.01). Conversely, women with PCOS-Ov showed similar total 
testosterone concentrations (P=0.21) and mean follicle counts (P=0.34) to Controls. They also 
had shorter menstrual cycle lengths (P=0.01), lower total testosterone concentrations (P=0.04), 
and lower free androgen indices (P=0.01) compared to the PCOS-Ov group (Table 2.3). 
 
Between-Group Differences in Ovarian Morphology 
 Follicle diameter populations (2–9 mm, 2–5 mm, 6–9 mm) and mean ovarian volumes 
were averaged over the entire scanning interval and are shown for the PCOS-Anov, PCOS-Ov, 
and Control groups in Figure 2.3. Women with PCOS-Anov were distinguished from Controls by 
higher numbers of total (2–9 mm; P<0.01) and small follicles (2–5 mm; P=0.01), as well as larger 
ovarian volumes (P=0.03). Conversely, women with PCOS-Ov showed similar follicle counts and 
ovarian volumes to both women with PCOS-Anov and Controls. Mean numbers of medium-sized 
follicles (6–9 mm) did not differ across groups (Overall: P=0.13) (Figure 2.3). 
  
Between-Group Differences in Correlates of Aberrant Folliculogenesis  
 Endocrine and metabolic features are compared among the PCOS-Anov, PCOS-Ov, and 
Control groups in Table 2.4. Mean concentrations of pituitary and ovarian hormones did not differ 
across groups (overall for all hormones: P>0.05). Consistent with the inclusion criteria for the 
present analysis, women with PCOS were largely obese, and Controls were normal weight (BMI 
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<25.0 kg/m2). Women with PCOS also demonstrated greater total and abdominal adiposity than 
Controls (both features, PCOS-Anov versus Control: P<0.01; PCOS-Ov versus Control: P<0.01), 
and waist circumference (P<0.01) and waist-to-hip ratio (P=0.02) differed between the two 
groups. Women with PCOS showed higher fasting insulin concentrations (PCOS-Anov versus 
Control: P<0.01; PCOS-Ov versus Control: P=0.04), higher HOMA-IR values (PCOS-Anov versus 
Control: P<0.01; PCOS-Ov versus Control: P=0.02), and lower WBISI values compared to 
Controls (PCOS-Anov versus Control: P<0.01; PCOS-Ov versus Control: P<0.01) (Table 2.4). 
Overall, the PCOS-Anov and PCOS-Ov groups did not differ in any of the endocrine or metabolic 
features evaluated (Table 2.4).
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Table 2.3. Differences in diagnostic features between the PCOS-Anov, PCOS-Ov, and Control groups 
 
PCOS-Anov 
(n = 11) 
PCOS-Ov 
(n = 13) 
Controls 
(n = 11) 
Menstrual cycle length (d) 197 ± 138 (50, 365)aǂ 75 ± 44 (41, 180)bǂ 29 ± 2 (24, 31)c 
Hirsutism score 8 ± 4 (1, 15)a 6 ± 4 (2, 12)a 2 ± 3 (0, 6)b 
Total testosterone (ng/dl) 67.8 ± 27.9 (32.9, 118.0)a 44.6 ± 21.0 (15.8, 81.5)b 30.5 ± 9.6 (17.6, 43.6)b 
Free androgen index 11 ± 6 (4, 23)a 6 ± 3 (1, 15)b 2 ± 1 (1, 3)c 
Mean follicle number per ovary 50 ± 22 (14, 80)a 37 ± 20 (14, 84)ab 26 ± 7 (15, 36)b 
Mean ovarian volume (ml) 16 ± 4 (7, 21)a 12 ± 5 (7, 20)a 6 ± 4 (2, 12)b 
Data are presented as mean ± SD (minimum, maximum). a,b,c Within rows, uncommon superscripts denote significant differences between groups determined by one-way ANOVA 
with post-hoc Tukey’s HSD test, p<0.05. Diagnostic endpoints were evaluated on a single day of the scanning interval and with respect to stage of cycle. ǂ Data related to menstrual 
cycle length were censored to the year prior to enrollment (i.e. 365 days). 
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Figure 2.3. Mean values of sonographic endpoints during the entire scanning interval for women 
in the PCOS-Anov, PCOS-OV, and Control groups. Box-and-whisker plots are shown for three 
follicle size populations (2–9 mm, 2–5 mm, 6–9 mm) and ovarian volume. The box represents the 
25th and 75th percentiles and the horizontal line within the box represents the median. The 5th 
to 95th percentile range is reflected by the vertical bars. Outliers, if any, are denoted by dots. 
Uncommon letters denote significance differences between groups, p<0.05. 
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Table 2.4. Differences in correlates of aberrant folliculogenesis between the PCOS-Anov, PCOS-Ov, and Control groups  
 PCOS-Anov 
(n = 11) 
PCOS-Ov 
(n = 13) 
Controls 
(n = 11) 
Endocrine    
FSH (mIU/ml) 6.0 ± 1.9 (2.7, 9.2)a 6.5 ± 2.0 (2.7, 9.4)a 8.1 ± 2.2 (5.2, 12.3)a 
LH (mIU/ml) 7.4 ± 2.2 (3.0, 9.7)a 6.9 ± 3.6 (1.6, 14.3)a 4.8 ± 2.0 (2.0, 8.3)a 
Estradiol (pg/ml) 59.4 ± 19.7 (28.2, 94.8)a 56.7 ± 23.6 (24.8, 104.0)a 42.5 ± 25.0 (26.8, 97.9)a 
Metabolic    
BMI (kg/m2) 36.3 ± 8.0 (26.5, 48.4)a 34.8 ± 6.2 (25.7, 46.2)a 23.9 ± 1.9 (21.2, 27.3)b 
WC (cm) 109 ± 23 (76, 157)a 99 ± 16 (71, 127)ab 82.3 ± 7.2 (73, 94)b 
Waist-to-hips ratio 0.91 ± 0.09 (0.76, 1.08)a 0.86 ± 0.06 (0.75, 0.98)ab 0.81 ± 0.05 (0.73, 0.88)b 
Body fat (%) 40 ± 6 (30, 48)a 41 ± 6 (31, 46)a 28 ± 6 (19, 37)b 
Abdominal fat (%) 42 ± 7 (32, 52)a 40 ± 8 (25, 50)a 25 ± 7 (15, 37)b 
Fasting insulin (mIU/ml) 21.6 ± 18.9 (2.2, 56.1)a 12.3 ± 4.9 (7.1, 22.0)a 6.0 ± 3.8 (2.0, 14.3)b 
HOMA-IR 5.5 ± 4.8 (0.5, 14.7)a 3.0 ± 1.2 (1.6, 5.4)a 1.4 ± 0.8 (0.5, 2.6)b 
WBISI 4.4 ± 4.8 (0.6, 15.7)a 3.9 ± 1.8 (1.6, 7.4)a 12.7 ± 5.6 (6.2, 21.4)b 
Data are presented as mean ± SD (minimum, maximum). a,b Within rows, uncommon superscripts denote significant differences between groups determined by one-way ANOVA with 
post-hoc Tukey’s HSD test, p<0.05. Metabolic and endocrine endpoints were evaluated on a single day of the scanning interval and with respect to stage of cycle. Abbreviations: FSH, 
follicle-stimulating hormone; LH, luteinizing hormone; BMI; body mass index; WC, waist circumference; HOMA-IR, homeostatic model assessment of insulin resistance; WBISI, whole-
body insulin sensitivity index. 
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DISCUSSION 
 Our data are unique, in that they provide the first-ever longitudinal evidence that some 
follicles in polycystic ovaries can “escape” arrest and progress through advanced stages of 
maturation during natural cycles. Through comprehensive sonographic analyses, we described 
the trajectory of this development and identified differences in ovulatory follicle growth kinetics 
between women with PCOS and Controls. We also found that milder reproductive and endocrine 
abnormalities were associated with sporadic ovulatory cycles versus continued anovulation. 
Although our study was not designed to appreciate the implications of this altered growth in 
ovulatory follicles fully, our data do raise important questions regarding the actual relevance 
and/or health benefits of sporadic cycles in women with PCOS.  
 Ovulatory follicles were selected after shorter growth phases and at smaller diameters in 
women with PCOS-Ov compared to Controls. To the best of our knowledge, early selection has 
never been reported during natural or induced cycles in PCOS. This novel finding supports the 
notion that granulosa cells from polycystic ovaries prematurely acquire LH receptors.58 The theory 
of follicular arrest suggests that inappropriate exposure to LH can suppress granulosa cell 
proliferation and initiate atresia in non-dominant follicles.58,32 Yet, evidence of dominance and 
ovulation in our cohort indicates that some follicles can be “rescued” from arrest. Ovulatory 
follicles in normal ovaries are believed to have early morphologic and functional advantages over 
other subordinate follicles.22 It might be speculated that follicles that progress to ovulation in 
polycystic ovaries have more granulosa cells and FSH receptors than follicles that are destined 
for arrest. This might result in an increased ability to produce estradiol86 and/or escape the 
detrimental effects of excessive and untimely LH exposure. That being said, these endocrine 
abnormalities have been linked to impaired oocyte development, failure of implantation, and 
miscarriage in PCOS.97,98 Rescuing a follicle from arrest may, therefore, have negative 
implications for oogenesis, luteal function, and endometrial receptivity.  
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Women with PCOS-Ov exhibited longer intervals from selection to ovulation and had 
slightly larger pre-ovulatory follicle diameters than Controls, but the significance of delayed 
ovulation in PCOS remains to be determined. Ovulatory follicle growth rates and pre-ovulatory 
diameters in the PCOS-Ov group were in line with ranges that have been reported in healthy 
women during natural cycles.43,45 Therefore, longer growth phases from selection to ovulation 
likely reflected earlier selection alone, since overall growth intervals did not differ between women 
with PCOS-Ov and Controls. Because the timing of ovulation depends on a hormonal interplay 
between the hypothalamus, pituitary, and ovary, comprehensive endocrine profiles during the 
periovulatory period are needed to fully appreciate the degree to which ovulatory events differed 
between groups. 
Milder reproductive features were associated with sporadic ovulation in PCOS. Women 
with PCOS-Ov had shorter cycles, lower total testosterone, and lower free androgen indices than 
their anovulatory counterparts. Mean hirsutism scores, follicle number per ovary, and ovarian 
volume were also intermediate to women with PCOS-Anov and Controls. The observation that 
women with anovulatory intervals were largely hyperandrogenic supports the notion that 
androgens are a main driver of abnormal follicular maturation in PCOS.47 Similarly, the 
observation that women with sporadic ovulatory cycles were largely normoandrogenic (62%) 
supports the notion of an inverse association between androgens and degree of reproductive 
disturbance.88 We anticipated greater differences in endocrine and metabolic features between 
the PCOS-Anov and PCOS-Ov groups. Gonadotropins and markers of insulin sensitivity were 
intermediate in women with PCOS-Ov compared to women with PCOS-Anov and Controls, but 
differences did not reach significance. The theory that milder endocrine and metabolic 
disturbances can enable aspects of “normal” folliculogenesis in PCOS is consistent with our 
previous studies showing a higher incidence of dominant follicles in women with better insulin 
sensitivity64 and the inverse association between androgens and follicle number.88 It is likely that 
we did not detect differences in endocrine and metabolic status between groups, because women 
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with PCOS-Ov still represented a severe phenotype of the condition. Sporadic ovulation was a 
chance finding and was not indicative of normal ovulatory status. Cross-sectional assessments 
of clinical features may not have been sufficient to capture more transient improvements in 
endocrine and metabolic health. In the same way, our sample size (PCOS, n = 24) was sufficient 
to fulfill our primary objective of describing follicle growth kinetics over time (α = 0.05, power = 
80%). However, this analysis was largely serendipitous and not powered to detect smaller 
endocrine or metabolic differences between PCOS-Anov and PCOS-Ov. 
This study’s strengths lie in the assessment of growth dynamics of individual identified 
ovulatory follicles over time. Serial changes in follicle diameter were captured in the context of 
follicular excess and compared with mean outcomes and clinical features over the scanning 
interval. However, we acknowledge that interpretation of these findings is limited by the lack of 
concurrent serial endocrine data. Additional studies are required to determine the associations 
between altered follicle growth kinetics and serial changes in gonadotropins and ovarian steroids. 
Such assessments will enable more discrete assessments of follicular and luteal function and are 
ultimately needed to capture any impact/health benefits of sporadic ovulation in PCOS. Chronic 
anovulation alone is associated with osteoporosis,99 cardiovascular disease,100 and gynecologic 
cancers.101 Having sporadic ovulations may, therefore, reduce the risk for these poor health 
outcomes. Similarly, women with ovulatory phenotypes of PCOS are expected to have lower 
morbidity and mortality across the lifespan, though longitudinal data are still needed.102 
In summary, ovulatory follicle growth kinetics are altered during sporadic ovulatory cycles 
in PCOS. Future assessment of these data, in conjunction with endocrine dynamics, will enable 
a better understanding of the mechanisms that govern oocyte development, luteal function, and 
endometrial receptivity in PCOS. Androgen excess may be an important target for interventions 
aimed at reinstating ovulation in this population.
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CHAPTER 3 
UTILITY OF THE UPDATED ULTRASOUND CRITERIA FOR  
POLYCYSTIC OVARY SYNDROME ACROSS THE MENSTRUAL CYCLE 
 
ABSTRACT 
 
Objectives. Diagnosis of polycystic ovary syndrome (PCOS) requires sonographic evaluation of 
polycystic ovarian morphology (PCOM) during the early follicular phase of a natural or induced 
cycle. This approach is based on evidence that follicle number and ovarian size can fluctuate 
during the normal menstrual cycle. The objective of this study was to determine the impact of a 
dominant follicle or corpus luteum on the morphologic diagnosis of PCOS.  
 
Methods. Twenty-six women with irregular menstrual cycles and PCOS were evaluated by serial 
ovarian ultrasonography for 3–6 weeks. Mean follicle number per ovary (FNPO), follicle number 
per cross-section (FNPS), and ovarian volume (OV) were quantified every other day throughout 
the study. Changes in each marker were assessed across a random anovulatory interval (PCOS-
ND, n=8) and different phases of the menstrual cycle (PCOS-D, n=18).  
 
Results. Mean values for FNPO and OV exceeded the diagnostic thresholds on each day of the 
study in the PCOS-ND and PCOS-D groups. FNPO remained constant throughout the random 
anovulatory interval (PCOS-ND, P=0.23) and menstrual cycle (PCOS-D, P=0.48). Similar to 
previous reports in women with regular cycles, OV increased during the luteal phase (PCOS-D, 
P<0.01) and resulted in more false-positive diagnoses of PCOM (P=0.06). Conversely, mean 
values for FNPS fell below the diagnostic threshold on most days of the study in the PCOS-ND 
and PCOS-D groups. FNPS was largely impacted by image quality (PCOS-ND, 30% variance) 
and stage of cycle (PCOS-D, P<0.01).  
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Conclusions. FNPO was the most robust morphologic marker of PCOS over time. Diagnostic 
evaluations of OV were altered by the presence of a dominant follicle and a corpus luteum, and 
should, therefore, be confined to the early follicular phase. FNPS was an inconsistent marker of 
PCOM across the menstrual cycle; its use as a surrogate for FNPO should be avoided.
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INTRODUCTION 
Polycystic ovarian morphology (PCOM) has long been associated with the condition of 
polycystic ovary syndrome (PCOS). The first description of PCOM came in 1935, when Stein and 
Leventhal observed bilateral polycystic ovaries in seven women with amenorrhea.16 Decades 
later, three seminal studies established follicular excess and stromal hypertrophy as 
morphological hallmarks of the condition.53,55,54 The application of high-resolution ultrasound 
technology enabled non-invasive evaluation of these features and highlighted the high prevalence 
of PCOM in women with anovulation or androgen excess.14 Over time, consensus mounted in 
both clinical and research communities that PCOM represents an important diagnostic marker of 
PCOS.6,8,9,14 
As such, reliable and accurate morphological criteria are needed to distinguish normal 
ovaries from polycystic ovaries.18 This was formally appreciated in 2003, when an expert panel 
proposed the first diagnostic thresholds for PCOM.8,9 These “Rotterdam criteria” identified follicle 
number per ovary (FNPO) and ovarian volume (OV) as accurate sonographic markers of the 
polycystic ovary and defined PCOM by an FNPO ≥12 follicles or OV ≥10 ml.8,9 The panel also 
recommended that transvaginal approaches be used, that women be scanned at a random time 
or after a progestin-induced withdrawal bleed, and that the presence of a dominant follicle or 
corpus luteum be sufficient to delay evaluation. The thresholds were established using the only 
diagnostic test study available103 and technical aspects were based on expert opinion.8,9,20  
Dissemination of these criteria into clinical practice led to controversy over the specificity 
of PCOM to the condition of PCOS. Numerous reports began to suggest that the thresholds were 
inappropriate and contributed to a false diagnosis in >60% of healthy women.104,105 Many 
clinicians and researchers argued that the clinical and biochemical criteria were paramount to 
detect PCOS – with little information garnered from sonographic evidence.14,15 At the same time, 
others urged that the morphological criteria just needed further attention, with a comprehensive 
evaluation of normative data and any impact of newer imaging technology.66,106,107 In 2012, the 
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National Institutes of Health prioritized these evaluations in the national research agenda for 
PCOS.6  
Recently, the Androgen Excess and PCOS (AE-PCOS) Society responded with a revised 
definition for PCOM.19 FNPO and OV were reaffirmed as accurate reflections of follicular excess 
and stromal hypertrophy, and a thorough review of available literature was conducted to identify 
ranges for these metrics in healthy women.19 This process resulted in two notable changes from 
the Rotterdam criteria. First, the diagnostic threshold for FNPO was raised from ≥12 to ≥25 
follicles. Second, the threshold for OV was maintained at ≥10 ml, but recommended use of the 
marker was limited to cases of poor image quality or older technology (i.e. <8MHz).19 The panel 
acknowledged that FNPO had superior sensitivity to detect PCOS66,107 and that the utility of any 
other common metrics (i.e., follicle number per cross-section, FNPS) remained uncertain.19,66 
Other technical aspects, related to the timing of evaluation, were not directly addressed. 
Ultimately, these new thresholds are expected to improve the sonographic evaluation of 
PCOM.19 However, their biological accuracy remains in question. A main issue relates to the 
permanence of follicular excess over time. In healthy women of reproductive age, follicle 
populations have been shown to fluctuate from day-to-day and between the follicular and luteal 
phases of the menstrual cycle.22 Ovarian size has also been shown to increase with the growth 
of a dominant follicle or corpus luteum.108 In clinical practice, these anatomical changes provide 
important rationale for limiting diagnostic evaluations to the early follicular phase of a natural or 
induced cycle.8,9,20 However, performing multiple ultrasound scans may not be feasible in certain 
practices or resource-limited settings. Patients may have to travel from remote locations for care 
and insurance providers may only cover the cost of one diagnostic visit. Thus, the time and cost 
associated with additional ultrasound scans may impart a significant burden on women. Likewise, 
in research settings, the inconvenience of multiple scans for ensuring eligibility may hinder 
enrollment and retention of participants. It is worthwhile to understand whether fluctuations in 
follicle number or ovarian size impact the utility of the morphological criteria to detect PCOS. 
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Our recent evaluation of antral follicle dynamics in anovulatory (Chapter 1) and sporadic 
ovulatory cycles (Chapter 2) provides a unique opportunity to address this question. In the present 
analysis, our objective was to assess the impact of a dominant follicle or corpus luteum on the 
morphologic diagnosis of PCOS. Based on evidence from our diagnostic test studies, we 
hypothesized that FNPO would be the most robust marker of polycystic ovarian morphology over 
time. We further hypothesized that both FNPS and OV would be impacted by cycle phase, 
because these measurements are based on very limited views of the ovaries.
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METHODS 
 
Ethical Considerations 
This observational study included data that were collected as part of two study protocols 
(ClinicalTrials.gov Identifiers: NCT01927432, NCT01785719) between 2009 and 2016. Both 
protocols were approved by the Institutional Review Board at Cornell University, and informed 
consent was obtained from all participants before study procedures were initiated.  
 
Study Participants 
 Twenty-six overweight and obese women (body mass index, BMI ≥25 kg/m2) with irregular 
menstrual cycles and PCOS were recruited from the general population (Chapter 1 and Figure 
3.1). PCOS was diagnosed by the Rotterdam criteria, as previously described (Chapter 1). To be 
eligible, participants had to be 18 to 38 years old, have normal serum concentrations of thyroid-
stimulating hormone and prolactin,7 and have consistent resolution of both ovaries on 
ultrasonography. Exclusion criteria included use of medications known or suspected to interfere 
with reproductive function in the two months prior to the study, recent pregnancy or lactation, 
history of premature ovarian failure or surgery, and medical conditions expected to interfere with 
study participation (Chapter 1).   
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Figure 3.1.  Flow of participants through the observational cohort study (2009–2016) and present 
analysis. Shaded boxes designate the cohorts from which participants were selected for the 
present analysis. Abbreviations: PCOS, polycystic ovary syndrome; BMI, body mass index. 
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• Irregular cycles alone (n = 3) 
• Elevated prolactin (n = 1) 
• Poor visualization of at least 
one ovary during study (n = 2) 
• Other reasons (n = 2) 
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Ultrasonographic Measurements 
Transvaginal ultrasonography was used to prospectively evaluate ovarian morphology 
(Chapter 1). Scans began at a random time and were performed every other day for 3–6 weeks. 
Follicular growth was closely monitored in real-time. If a large follicle (≥14 mm) was detected, 
then ultrasound examinations were performed daily until its regression or ovulation. Ovulation 
was identified by the observation of a corpus luteum.73,74 Whole ovaries were imaged from their 
inner to outer margins in the longitudinal plane using a GE Voluson E8 Expert System and 6–12 
MHz transducer (Chapter 1). Digital ultrasound images were archived for offline analysis by a 
single investigator (Santesoft LTD, Athens, Greece).  
Ultrasound images of each ovary were analyzed for three parameters: (1) FNPO, (2) 
FNPS, and (3) OV. Cineloops throughout each ovary were evaluated for FNPO. Follicles ≥2 mm 
were counted and measured,75 and the presence of a dominant follicle (≥10 mm) or corpus luteum 
was recorded. The largest cross-sectional view of each ovary was evaluated for FNPS and OV.93 
OV was calculated with the equation: π/6 × (transverse diameter) × (longitudinal diameter) × 
(anteroposterior diameter).20,94 The image quality of each dataset was also subjectively 
categorized into one of three groups (1 = Poor, 2 = Partially Visible, 3 = Excellent), based on the 
proportion of the ovarian contour and follicles that could be seen. A value for FNPO, FNPS, OV, 
and image quality was designated as the mean recorded values of the left and right ovaries for 
each participant and day of the study. 
 
Definitions 
 Following offline image analysis, participants were stratified into two groups based on the 
absence (PCOS-ND) or presence (PCOS-D) of a dominant follicle during the study (Figure 3.1). 
Data were then binned by cycle phase. Early follicular phase referred to a time after menses with 
no follicular development >9 mm. Mid- to late-follicular phase referred to a time from the first day 
a dominant follicle was detected to the last day before it ovulated, regressed, or the study ended. 
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Luteal phase referred to a time from the first day a corpus luteum was detected to the last day 
before menses or the study ended. 
  
Statistical Analyses 
Statistical analyses were performed with JMP Pro 12.0.1. (SAS Institute, Cary, NC); the 
threshold for statistical significance was set at P≤0.05. Descriptive statistics were tabulated for 
each endpoint. Normality was evaluated with histograms or residual plots, and skewed data were 
log-transformed prior to analyses. Cross-sectional data related to participant characteristics were 
compared between the PCOS-ND and PCOS-D groups using two-sample t-tests. Serial data 
related to sonographic endpoints were centralized to the first day of the study (PCOS-ND) or cycle 
phase (PCOS-D) and normalized over time. Group-specific mixed-effects models were performed 
to evaluate changes in FNPO, FNPS, and OV (i.e. an effect of day or cycle phase). The degree 
of intra-cycle versus inter-individual variation was considered. Participant number, participant 
number crossed with time, and participant number crossed with image quality were included as 
random effects in all models. Mean FNPO, FNPS, and OV across the anovulatory interval or cycle 
phase were calculated and a diagnosis was applied. The Cochrane Armitage Trend test was then 
used to determine differences in the probability of diagnosis over time. 
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RESULTS 
 
Characteristics of Study Participants 
Participant demographics and diagnostic features are presented in Table 3.1. Overall, 
women began the study at a random time, between four days and one year after their self-reported 
last menses. They were evaluated for an average of 31 days (range: 23–46 days). Eight of the 26 
women with PCOS did not exhibit a morphologic event during the study (i.e. PCOS-ND). No 
dominant or ovulatory follicles or corpora lutea were observed. Therefore, data collected from the 
women in this group represented a random time during the early follicular phase. By contrast, 18 
of the 26 women with PCOS exhibited at least one morphologic event during the study (i.e. PCOS-
D). Dominance (n=18) and sporadic ovulation (n=13) were observed. Therefore, data collected 
from the women in this group represented three phases of the menstrual cycle: (1) the early 
follicular phase (n=18); (2) the mid- to late-follicular phase (n=18); and (3) the luteal phase (n=13). 
Women were observed for an average of 13 days in the first phase (range: 2–28 days), 7 days in 
the second phase (range: 2–33 days), and 7 days in the third phase (range: 1–16 days). 
 Demographics and diagnostic features were compared between the PCOS-ND and 
PCOS-D groups (Table 3.1). Despite meeting the Rotterdam definition of PCOS, women with 
PCOS-D had milder reproductive features than women with PCOS-ND. Namely, women with 
PCOS-D reported shorter menstrual cycles (P=0.04), albeit still above the threshold for oligo- or 
amenorrhea (i.e. >35 days), and had lower total testosterone concentrations (P=0.05) (Table 3.1). 
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Table 3.1. Characteristics of study participants 
 
PCOS 
(n = 26) 
PCOS-ND  
(n = 8) 
PCOS-D 
(n = 18) 
Age (y) 27 ± 5 (20, 36) 26 ± 4 (21, 31)a 28 ± 5 (20, 36)a 
Body mass index (kg/m2) 35.3 ± 6.7 (25.7, 48.4) 36.8 ± 8.9 (26.4, 48.4)a 34.7 ± 5.7 (25.7, 46.2)a 
Menstrual cycle length (d) 119 ± 106 (41, 365)ǂ 198 ± 144 (50, 365)aǂ 78 ± 43 (41, 180)bǂ 
Hirsutism score 7 ± 4 (1, 15) 7 ± 4 (1, 14)a 7 ± 4 (2, 15)a 
Total testosterone (ng/dl) 54.7 ± 25.9 (15.8, 118.0) 73.1 ± 31.4 (32.9, 118.0)a 46.0 ± 17.9 (15.8, 81.5)b 
Free androgen index 8 ± 5 (1, 23) 11 ± 7 (4, 23)a 6 ± 4 (1, 15)a 
Mean FNPO 42 ± 20 (14, 84) 54 ± 24 (14, 80)a 37 ± 16 (14, 84)a 
Mean FNPS 8 ± 4 (2, 21) 9 ± 5 (3, 15)a 8 ± 4 (2, 21)a 
Mean OV (ml) 14 ± 5 (7, 21) 17 ± 5 (7, 21)a 13 ± 4 (7, 20)a 
Data are presented as mean ± SD (minimum, maximum). a, b Within rows, uncommon superscripts denote significant differences between the PCOS-ND and PCOS-D groups 
determined by t-test, P≤0.05. Diagnostic endpoints were evaluated on a single day of the scanning interval and with respect to stage of cycle. ǂ Data related to menstrual cycle length 
were censored to the year prior to enrollment (i.e. 365 days). Abbreviations: PCOS, polycystic ovary syndrome; PCOS-ND, women without evidence of a dominant follicle during the 
study; PCOS-D, women with evidence of a dominant follicle during the study; FNPO, follicle number per ovary; FNPS, follicle number per cross-section; OV, ovarian volume. 
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Changes in Sonographic Markers of PCOM in Women with PCOS-ND 
 Mean profiles of FNPO, FNPS, and OV across the random anovulatory interval are 
illustrated for women with PCOS-ND in Figure 3.2. Little fluctuation was observed in any of the 
three sonographic markers. Mean values for FNPO and OV seemed constant over time and 
exceeded the current diagnostic thresholds for PCOM on each day of the study. Conversely, 
mean values for FNPS seemed slightly more variable over time and exceeded the diagnostic 
threshold on some, but not all, of the days (Figure 3.2). Mixed-effects model analysis confirmed 
these observations (Table 3.2). There was no effect of day for FNPO (P=0.23), FNPS (P=0.95), 
or OV (P=0.60). Intra-cycle fluctuation accounted for less than one-third of the total variance in 
each marker (FNPO: 3%; FNPS: 29%; OV: 14%). Most of the remaining variance was attributed 
to inter-individual factors (FNPO: 87%; FNPS: 41%; OV: 85%) or image quality. Image quality 
had the greatest impact on FNPS (30%) and the smallest impact on OV (1%) (Table 3.2). 
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Figure 3.2. Profiles (mean ± SD) of sonographic markers of polycystic ovarian morphology during 
one random scanning interval in women with PCOS-ND (n = 8). The updated diagnostic threshold 
for each marker is depicted by a red line. Abbreviations: PCOS-ND, women without evidence of 
a dominant follicle during the study; FNPO, follicle number per ovary; FNPS, follicle number per 
cross-section; OV, ovarian volume. 
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Table 3.2. Mixed-effects model analysis of changes in sonographic markers of polycystic ovarian morphology during a random 
scanning interval in women with PCOS-ND (n = 8) 
 
 Intercept  Change over time  Components of total variance 
 β ± SE (95% CI)  β ± SE (95% CI) P value  
Intraindividual 
factors 
Interindividual 
factors 
Image  
quality 
Mean FNPO 59 ± 8 (40, 77)  –0.2 ± 0.1 (–0.5, 0.1) 0.23  3% 87% 10% 
Mean FNPS 9 ± 1 (7, 11)  0.0 ± 0.4 (–0.1, 0.1) 0.95  29% 41% 30% 
Mean OV (ml) 16 ± 2 (11, 21)  0.0 ± 0.4 (–0.1, 0.1) 0.60  14% 85% 1% 
Models included data collected every other day of the scanning interval (n = 16 data points per marker per woman). Abbreviations: PCOS-ND, women without evidence of a dominant 
follicle during the study; FNPO, follicle number per ovary; FNPS, follicle number per cross-section; OV, ovarian volume.  
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Changes in Sonographic Markers of PCOM in Women with PCOS-D 
 Mean profiles of FNPO, FNPS, and OV across the different phases of the menstrual cycle 
are illustrated for women with PCOS-D in Figure 3.3. Fluctuation was apparent in two of the three 
sonographic markers. Whereas mean values for FNPO seemed constant over time, FNPS and 
OV seemed to change, particularly in the luteal phase. Similar to the random anovulatory interval, 
mean values for FNPO and OV exceeded the current diagnostic thresholds throughout each cycle 
phase. However, FNPS remained below the threshold on all days of the study (Figure 3.3). Mixed-
effects model analysis confirmed these observations (Table 3.3). There was no effect of cycle 
phase for FNPO (P=0.48). However, FNPS (P<0.01) and OV (P<0.01) changed across the three 
cycle phases. Compared to the early follicular phase, the presence of a dominant follicle was 
associated with reduced values for FNPS (P=0.03). An active corpus luteum was also associated 
with reduced values for FNPS (P<0.01) and increased values for OV (P<0.02). Most of the 
variance was attributed to intra-cycle (FNPO: 14%; FNPS: 29%; OV: 33%) or inter-individual 
factors (FNPO: 82%; FNPS: 66%; OV: 66%). The impact of image quality was minimal (FNPO: 
4%; FNPS: 4%; OV: 0%) (Table 3.3).
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Figure 3.3. Profiles (mean ± SD) of sonographic markers of polycystic ovarian morphology across 
different phases of the menstrual cycle in women with PCOS-D. The updated diagnostic threshold 
for each marker is depicted by a red line. Abbreviations: PCOS-D, women with evidence of a 
dominant follicle during the study; FNPO, follicle number per ovary; FNPS, follicle number per 
cross-section; OV, ovarian volume. 
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Table 3.3. Mixed-effects model analysis of changes in sonographic markers of polycystic ovarian morphology between different phases 
of the menstrual cycle in women with PCOS-D 
 
 Estimate per cycle phase 
 
Overall change 
 
Early follicular phase  
(n = 18) 
Mid- to late- follicular 
phase (n = 18) 
Luteal phase  
(n = 13) 
 
P value 
Mean FNPO 38 ± 4 (29, 46) 36 ± 4 (27, 44) 35 ± 4 (27, 44) 
 
0.48 
Mean FNPS 7 ± 1 (6, 9)a 7 ± 1 (5, 8)b 6 ± 1 (4, 7)b 
 
<0.01 
Mean OV (ml) 12 ± 1 (10, 15)a 13 ± 1 (11, 16)a 16 ± 1 (13, 18)b 
 
<0.01 
Estimates per cycle phase are presented as least squares mean ± SE (95% CI). Models included data collected every other day during each cycle phase (n = 4–7 data points per 
marker per woman). a, b Within rows, uncommon superscripts denote significant differences between cycle phases determined by post-hoc Tukey’s HSD tests, p<0.05. Abbreviations: 
PCOS-D, women with evidence of a dominant follicle during the study; FNPO, follicle number per ovary; FNPS, follicle number per cross-section; OV, ovarian volume.  
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Proportion of Women Diagnosed with PCOM by Each Marker 
The percentage of women diagnosed with PCOM by each marker is shown for the two 
groups in Figure 3.4. In the PCOS-ND group (n=8), most women met the current sonographic 
criteria for PCOM by FNPO (100%) and OV (86%). Only half of the women met the criteria by 
FNPS (50%). A similar case was apparent in the PCOS-D group (n=13). Across cycle phases, 
there were no differences in the percentage of women diagnosed with PCOM by FNPO (P=0.65) 
or FNPS (P=0.61). However, slightly more women were identified as having PCOM by OV in the 
luteal phase than in the follicular phase (P=0.06) (Figure 3.4). 
 
Figure 3.4. Percentage of women meeting the updated diagnostic criteria for polycystic ovarian 
morphology (A) at any given time during the random scanning interval (n = 8) and (B) across 
different phases of the menstrual cycle (n = 13). Mean data related to the early follicular phase 
(black), mid- to late-follicular phase (dark gray), and luteal phase (light gray) are represented. 
Abbreviations: FNPO, follicle number per ovary; FNPS, follicle number per cross-section; OV, 
ovarian volume. 
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DISCUSSION 
The objective of the present study was to evaluate the impact of a dominant follicle or 
corpus luteum on the morphologic diagnosis of PCOS. We observed that FNPO was constant 
across a random anovulatory interval (PCOS-ND) and different phases of the menstrual cycle 
(PCOS-D). We documented an increase in OV during the luteal phase, which contributed to an 
increase in the number of false-positive diagnoses of PCOM. Further, we found that FNPS was 
an inconsistent marker of PCOM over time and that its assessment was impacted by both image 
quality (PCOS-ND) and stage of cycle (PCOS-D). 
Our results suggest that FNPO is a robust marker of PCOM in women with PCOS. FNPO 
consistently exceeded the current diagnostic threshold in women with (PCOS-D) and without 
(PCOS-ND) dominant follicle development. In addition, there was non-significant intra-cycle 
variation in FNPO across the random anovulatory interval (3%) and different phases of the 
menstrual cycle (14%). Minimal variation in FNPO during a random anovulatory interval is 
consistent with findings from our recent serial evaluation of antral follicle populations in PCOS 
(Chapter 1). The repeated findings are not surprising, because the same participants were 
included in both studies. However, the permanence of follicular excess over time is compelling. It 
reaffirms the predictive power of FNPO for the condition of PCOS66,93 and speaks to the 
interchangeable nature of FNPO and antral follicle count (i.e. AFC; FNPO × 2) – a marker 
commonly used to assess ovarian reserve and response to assisted reproduction therapies.109  
Greater variation in FNPO during the menstrual cycle versus anovulatory interval may be 
related to changes in the number of large follicles (≥5 mm), which are known to accompany 
follicular development in healthy women.44 Indeed, significant changes in AFC (2–10 mm) have 
been reported during the mid-follicular and luteal phases in this population.79 Although similar 
patterns were not detected in our study, there may be relevance to exploring alternative metrics 
to detect PCOM outside of the early follicular phase. Deb and colleagues noted that the number 
of small follicles (2–6 mm) showed little intra-cycle variation and excellent correlation between 
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different cycle phases in healthy women.79 Similarly, we (Chapter 1) and others57,103 have found 
that the number of small follicles (2–5 mm) can reflect follicular excess over time in women with 
PCOS. The evaluation of this follicle population in clinical practice is onerous, since counts are 
performed manually, and polycystic ovaries can contain >75 small follicles on any given day 
(Chapter 1). However, emerging ultrasound technology, designed to automatically count, 
measure, and classify follicles by size, holds promise to improve the efficiency of this process.110 
Future studies are needed to evaluate the utility of different metrics and automated technologies 
to assess PCOM.  
Nevertheless, the clinical usefulness of AFC remains unchanged across the menstrual 
cycle in healthy women.111,112 Variations in AFC do not impact its ability to reflect ovarian reserve 
or inform ovarian response to assisted reproduction therapies.111,112 Similarly, the variations in 
FNPO did not impact its ability to detect PCOS over time in this study. We noted that inter-
individual differences accounted for >80% of the variation in FNPO. Because the AFC is 
considered an accurate marker of the ovarian reserve,109 this finding likely reflects differences in 
ovarian reserve among women in our cohort. It has been suggested that women with PCOS are 
born with a larger pool of resting follicles than controls,113 but the extent to which ovarian reserve 
may differ among patients is unknown.  
Our results suggest that FNPS is the least consistent marker of PCOM in women with 
PCOS. In both the PCOS-ND and PCOS-D groups, FNPS fell at or below the recommended 
diagnostic threshold on most days of the study. There was similar intra-cycle variation in FNPS 
across a random anovulatory interval (29%) and different phases of the menstrual cycle (29%). 
Such variation did not improve the ability of FNPS to detect PCOS over time. However, it indicated 
that assessments of the marker may be influenced by biological and technical factors. Specifically, 
substantial intra-cycle variation in FNPS reflected aspects of antral follicle development. Despite 
similar mean values over time, FNPS was significantly higher in the early follicular phase than in 
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the mid-to-late follicular or luteal phases. This suggests that FNPS was impacted by the presence 
of a dominant follicle and corpus luteum.  
FNPS is widely used in clinical practice due to the convenience of acquiring still images 
versus video clips of the ovary. However, its utility compared with FNPO or OV is debatable.19,66 
We recently showed that FNPS has the poorest diagnostic potential of the three markers to detect 
PCOS.93 We have hypothesized that this relates to the limitations of performing follicle counts 
when only a single cross-sectional view of the ovary is made available.66 This approach relies 
heavily on the interpretive skills of the observer. It can be challenging to subjectively identify the 
largest plane of the ovary, resolve any anechoic regions, and discriminate between artifact and 
follicles under these conditions. We have previously reported that diagnostic confidence (as 
judged by the observer) in identifying PCOM is substantially lower when individuals are limited to 
performing follicle counts in a single cross-section compared to the entire ovary.66 As a result, 
random fluctuations over time in FNPS might be expected. The notion that such fluctuation is 
linked to the observer is supported by our observation that image quality had a greater impact on 
FNPS than on other markers. We attempted to control for an impact of image quality by limiting 
study enrollment to women with excellent resolution of their ovaries on ultrasound. However, it 
was not unusual for an ovary to have reduced visibility from shadowing by bowel or the uterus on 
any given day. We suspect that we were more conservative with follicle counts in these cases, 
thereby resulting in lower detection rates of PCOM.  
Our results suggest that OV is a robust marker of PCOM in women with PCOS – but only 
during the follicular phase. In both the PCOS-ND and PCOS-D groups, OV exceeded the current 
diagnostic threshold on each day of the study. There were substantial intra-cycle variations in 
FNPO across the random anovulatory interval (14%) and different phases of the menstrual cycle 
(33%). Intra-cycle variation during the random anovulatory interval was non-significant, but also 
greater than expected. Ovarian size has been shown to increase with the growth of a dominant 
follicle or corpus luteum.108 However, these events did not occur during the anovulatory interval. 
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The absence of concurrent fluctuation in FNPO suggests that two-dimensional assessments of 
OV may suffer from the same technical limitations as described for FNPS. That is, selection of 
the largest cross-sectional view of the ovary may differ from day to day, and in the current 
analysis, may have impacted estimates of OV. Intra-cycle variation did not appear to change the 
likelihood of diagnosis with PCOM, but these outcomes could not be quantitatively assessed. 
Three-dimensional approaches may hold promise for more reliable evaluations of OV over time.114 
Conversely, intra-cycle variation across different phases of the menstrual cycle was 
significant and expected.108 OV increased from the follicular phase to the luteal phase. This 
observation reflected the growth of a corpus luteum in the luteal phase, which has been shown to 
comprise a large proportion of the ovarian tissue.74 Substantial inter-individual variation (66%) in 
OV was likely related to differences in the types and sizes of corpora lutea detected among 
women.74 An increase in OV during the luteal phase contributed to several false-positive 
diagnoses of PCOM. When evaluated by this marker alone, four participants transitioned from 
normal ovarian morphology in the follicular phase (i.e. OV <10 ml) to PCOM in the luteal phase 
(i.e. OV >10 ml). Notably, each of these women consistently met the diagnostic criteria for PCOM 
by FNPO during the menstrual cycle. This is in line with our previous observations that FNPO has 
greater diagnostic potential compared with OV.66,93 Consequently, the use of FNPO to detect 
PCOM in these women may have obviated any concerns over misdiagnosis. Evaluation of OV in 
the non-dominant ovary (rather than taking the mean of both ovaries) may also be an appropriate 
approach in these cases. Clinicians often rely on metrics taken in the largest ovary to assign a 
diagnosis of PCOM. However, very little is known about inter-individual differences in ovarian 
morphology. Data from our group115 and others116 have suggested that the right ovary is larger 
than the left in controls and women with PCOS. Future studies are needed to corroborate an 
impact of sided differences on the diagnosis of PCOM before a recommendation can be made.  
 Last, we noted that image quality had the smallest impact on OV across the random 
anovulatory interval (1%) and different phases of the menstrual cycle (0%). This is consistent with 
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the current recommendation that OV be used to detect PCOM in the event of poor image quality 
or with older imaging technology (i.e. <8 MHz).  
It is important to acknowledge that the actual relevance of ovarian morphology to the 
diagnosis of PCOS is unknown. Currently, the confirmation of PCOM on ultrasonography does 
not modify a diagnosis based on the presence of oligo- or anovulation and hyperandrogenism.8,9,17 
We found that 69% of the women in our study had a hyperandrogenic phenotype (i.e. Frank or 
Non-PCOM PCOS). Ultrasonography may only be helpful for these patients when access to a 
reliable androgen assay is limited.117 Conversely, 31% of the women in our study had a 
normoandrogenic anovulatory phenotype (i.e. Mild PCOS). Reliable metrics to detect PCOM are 
the most relevant for this population. On average, women in the PCOS-D group were 
normoandrogenic and appeared to have lower FNPO and OV, though the differences did not 
reach significance. Future studies are needed to resolve whether the revised criteria for PCOM 
can adequately distinguish normoandrogenic women from healthy controls across the menstrual 
cycle. It is possible that the addition of functional ovarian markers (i.e. anti-Müllerian hormone) 
may improve the sonographic evaluation of PCOS.118  
A major limitation of this study was the evaluation of only overweight and obese women 
with PCOS. The current morphologic criteria for PCOS were established in a cohort of >1,000 
healthy women with normal BMIs. This is problematic, because overweight and obese women 
show a tendency for larger ovaries compared to their normal-weight counterparts, irrespective of 
PCOS status.19 Emerging data from our group and others also suggest that obesity adversely 
impacts folliculogenesis in women with and without PCOS.84,119,120 Future studies are needed to 
assess the impact of BMI on the morphologic criteria for this condition. As such, we acknowledge 
that the outcomes reported in this study cannot be readily extrapolated to normal-weight women. 
In addition, we recognize that sonographic evaluations of PCOM are usually conducted after a 
progestin-induced withdrawal bleed in clinical practice. Our assessments occurred during a 
natural cycle after an extended period of anovulation. To the best of our knowledge, there are 
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little to no data assessing the dynamics of luteal function in women with PCOS. Therefore, it is 
unclear whether aspects of PCOM differ during a pharmacologically-induced versus natural 
follicular phase.  
 In summary, FNPO showed less intra-cycle fluctuation than OV and FNPS in women with 
PCOS. This suggests that FNPO is a robust marker of PCOM and that it can be assessed at a 
random time regardless of cycle phase. In the event of poor image quality or older imaging 
technology, OV can be used as an alternative marker of PCOM. However, caution should be 
taken during the luteal phase to minimize the risk of misdiagnosis. The predictive power of follicle 
counts and ovarian size for PCOS have been described elsewhere.66,93 This work extends these 
observations to further support FNPO as the most convenient marker of PCOM and strengthens 
the recommendation against the use of FNPS on its own to predict PCOS. 
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CHAPTER 4 
IMPACT OF HYPOCALORIC DIETARY INTERVENTION  
ON OVULATION IN OBESE WOMEN WITH PCOS 
 
Jarrett BY, Lujan ME. Impact of hypocaloric dietary intervention on ovulation in  
obese women with PCOS. Reproduction 2017; 153; R15–R27. 
 
ABSTRACT 
Polycystic ovary syndrome (PCOS) is a common cause of ovulatory dysfunction impacting women 
of reproductive age. Obesity and insulin resistance are thought to potentiate disruptions in antral 
follicle development that result in chronic anovulation, and as such, have become important 
therapeutic targets of dietary interventions aimed at weight loss. Caloric restriction has been 
shown to promote sporadic ovulation in obese women with PCOS, but improvements have 
occurred across a wide range of patients and little has been garnered about the factors that 
distinguish responders from non-responders. Further, few studies have evaluated the likelihood 
for modest weight loss to restore normal ovulatory cyclicity in PCOS. Consensus regarding the 
impact of dietary intervention on ovulation has been limited by variability in the measures used to 
characterize and report ovulatory status across studies. In response, this review provides an 
assessment of the evidence surrounding the effectiveness of hypocaloric dietary intervention to 
normalize ovulatory function in PCOS. The impact of physiological versus methodological factors 
on the evaluation of ovulatory status is discussed and recommendations to strengthen future 
studies in this area are provided. Ultimately, further research is needed to understand the optimal 
dietary or lifestyle approaches that promote ovulation and sustained improvements in 
reproductive function in PCOS.
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INTRODUCTION 
Polycystic ovary syndrome (PCOS) is the leading cause of anovulatory infertility and has 
broad implications for the reproductive and metabolic health of women across the lifespan.2 The 
reproductive phenotype manifests as anovulation, menstrual irregularity, and hyperandrogenism 
and reflects defects at multiple levels of the hypothalamic-pituitary-ovarian axis.47,46 The 
hypersecretion of luteinizing hormone by the pituitary and overproduction of androgens by the 
ovaries interact to impair ovarian antral follicle development.47,46 Abnormal folliculogenesis in 
PCOS is characterized by an accumulation of small follicles, inhibition of terminal follicular growth 
(called follicle “arrest”), and failure of the mechanisms driving morphologic selection and 
ovulation.47,46 Obesity is intimately linked with the pathogenesis of anovulation in PCOS (Figure 
4.1).67 Excess weight and visceral adiposity promote the development of insulin resistance and 
compensatory hyperinsulinemia,89 which are posited to exacerbate disruptions in antral follicle 
development47,46 and worsen the severity of the reproductive phenotype.68 Therefore, therapies 
that attenuate obesity and insulin resistance hold promise to normalize anovulation and 
hyperandrogenism in PCOS (Figure 4.1).  
Currently, dietary interventions involving caloric restriction are recommended to combat 
both reproductive and metabolic abnormalities in overweight and obese women with PCOS. 
2,7,62,121 Modest reductions in energy intake (500–1000 kcal/d) and weight (5–10%) have been 
shown to normalize gonadotropin secretion,122 reduce clinical and biochemical hyperandrogenism 
and improve insulin sensitivity in this population.62,123 Likewise, randomized and non-randomized 
trials have documented an increased frequency of spontaneous ovulation, menses and 
pregnancy with weight loss.62 These findings are thought to reflect a recovery of the hormonal 
features that underpin follicular excess and “arrest” in PCOS (Figure 4.1).123 However, there are 
several challenges to understanding the actual effectiveness of weight loss to stimulate ovulation 
or restore normal ovulatory function in overweight and obese patients. Despite evidence of 
ovulation following dietary interventions, variability in the measures used to report endpoints 
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across studies has prevented systematic assessments of the impact of weight loss on 
reproductive outcomes.123 Further, improvements in ovulation have been noted over a wide range 
of women,7,62 yet little work has been done to understand the factors that account for variability in 
the ovulatory response to caloric restriction.  
To that end, the purpose of this review was to assess the evidence surrounding the 
effectiveness of hypocaloric dietary intervention to normalize ovulatory function in PCOS. The 
occurrence of and factors associated with ovulation in response to modest weight loss are 
described. Particular consideration is given to inconsistencies in the methods used to characterize 
ovulatory status across studies. The impact of physiological and methodological factors on the 
evaluation of ovulatory potential prior to dietary intervention is also discussed. 
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Figure 4.1. Proposed mechanism by which hypocaloric dietary intervention promotes ovulation in obese women with PCOS. 
As shown in the gray inset, excess weight and visceral adiposity promote the development of insulin resistance and compensatory 
hyperinsulinemia. Both are posited exacerbate disruptions in antral follicle development, through a reciprocal relationship with 
hyperandrogenism. Insulin contributes to systemic hyperandrogenism by stimulating the production of androgens by the ovaries and 
inhibiting the synthesis of sex hormone-binding globulin by the liver. These direct (solid line) and indirect actions (dotted line) of insulin 
result in elevated circulating concentrations of bioavailable androgens. Androgens may promote preferential deposition of adipose 
tissue in the abdomen and can exacerbate insulin resistance through obesogenic mechanisms (solid line) or independently (solid line) 
by modifying insulin action in classic target tissues. Since dietary interventions attenuate obesity and insulin resistance (orange boxes 
and arrows), they hold promise to treat anovulation and hyperandrogenism in PCOS. 
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LITERATURE SEARCH AND SELECTION CRITERIA 
PubMed, CINAHL and the Cochrane Central Register of Controlled Trials were used to 
identify relevant studies published between January 1990 and March 2016. Bibliographies of 
related systematic or narrative review articles were also screened to identify additional studies. 
The search included a combination of keywords relevant to PCOS, dietary or lifestyle intervention, 
and ovulation and menstrual cyclicity. The Population, Intervention, Comparison, Outcome 
(PICO) framework was used to define the inclusion and exclusion criteria for studies a priori. 
Briefly, studies included in this review were limited to original research articles in which: (1) the 
patient population comprised only overweight or obese women with PCOS; (2) the dietary 
intervention involved reductions in energy intake that were intended to promote weight loss; and 
(3) the primary or secondary outcome of interest was ovulation. Only articles published in English 
were included. Overweight or obesity was defined as a BMI of 25.0–29.9 kg/m2 (overweight) or 
≥30 kg/m2 (obesity).124 PCOS was defined according to the National Institutes of Health (NIH)17 
or Rotterdam criteria.8,9 Randomized controlled trials and non-randomized intervention studies 
were considered. Trials that incorporated either supervised or unsupervised physical activity with 
caloric restriction were included. By contrast, studies with combined dietary and pharmaceutical 
interventions (i.e. metformin or clomiphene citrate) were excluded, unless the pharmaceutical 
therapy served as a comparison to changes in energy intake alone. The title and abstract of every 
record retrieved by this search strategy was checked to ensure that it aligned with the established 
inclusion criteria. Relevant articles were downloaded for full-text review. Data on general 
characteristics of the study, patient population, diagnosis of PCOS, inclusion and exclusion 
criteria, intervention design, measurement of ovulation and outcomes related to ovulatory function 
were extracted. 
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RESULTS 
 
Characteristics of the Studies Included for Review 
The search returned 4,046 records, including ones that were identified through electronic 
databases (n=3,319) and bibliographies of other reviews (n=727). Duplicates found using multiple 
databases, keywords and sources were removed (n=3,234). All remaining records (n=812) were 
evaluated in the context of the PICO framework, and 780 were excluded based on the information 
provided in the title and/or abstract. Thirty-two original research articles were selected for full-text 
review. Of these, 13 were excluded due to the inclusion of women without PCOS (n=2), use of 
inappropriate diagnostic criteria (n=1), use of eucaloric dietary interventions (n=3), or absence of 
outcome data on ovulation (n=7). Ultimately, 19 articles from 17 different studies were included 
for review. Two of the articles constituted secondary analyses125,126 of data collected during a 
previous dietary intervention.127,128  
Relevant study characteristics are summarized in Table 4.1. At enrollment, the mean age 
of participants ranged from 23 to 33 years and mean BMI was within the obese category (Table 
4.1, Column 2). All of the dietary interventions were aimed at modest weight loss, primarily through 
short-term reductions in energy intake. In general, women were prescribed a caloric deficit of at 
least 500 kcal per day and encouraged to restrict energy intake to between 1,000 and 1,400 kcal 
per day. Two studies used very low calorie diets (i.e. total energy intake <500 kcal per day)129,130 
(Table 4.1, Column 4). Despite being hypocaloric, the dietary interventions met national standards 
for carbohydrates (45–65% of calories), protein (10–35% of calories) and fat (20–35% of 
calories).131 Participants were largely required to purchase and prepare their own meals and 
snacks; four studies provided partial or complete meal replacements to aid in caloric 
restriction.127,129,130,132 Multifactorial approaches to enhance the target energy deficit and degree 
of weight loss were also common. Some studies modified macronutrient composition, 
recommended a specific frequency or intensity of physical activity, and/or delivered behavior 
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modification therapy through individual or group education sessions (Table 4.1, Column 5). 
Fifteen of the 17 studies were conducted over a period of three months or longer, wherein the 
duration of active weight loss ranged from six weeks133 to seven months134–137 (Table 4.1, 
Columns 3–4). At the end of the dietary interventions, mean reductions in body weight ranged 
from 3%128,136 to 16%138 (Table 4.1, Column 6). 
Improvements in ovulation were defined in one of two ways across studies: (1) the 
occurrence of one or two (“sporadic”) ovulations or (2) the resumption of regular (“monthly”) 
ovulatory cycles. Data were reported as the proportion of women with either ovulatory response 
or as the number of ovulatory menstrual cycles detected during the dietary intervention. Overall, 
most of the results on improved ovulatory function were presented as the number of women who 
experienced sporadic ovulation with weight loss. Only two of the studies assessed the occurrence 
of regular ovulatory cycles139,140 and none compared the likelihood for dietary intervention to 
stimulate a single ovulation versus restore normal ovulatory function. Similarly, three studies 
published data on the number of ovulatory menstrual cycles detected per woman or treatment 
group, but did not provide any additional information with which to characterize ovulatory 
cyclicity.134,135,137
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Table 4.1. Summary of studies of the impact of hypocaloric dietary intervention on ovulation in overweight or obese women with polycystic ovary syndrome (PCOS) 
 
First Author Population and Diagnosis Study Design Caloric Restriction Additional Approaches Weight Loss 
Guzick  
(1994) 
n=6 
Age 32y, IBW 176% 
OA + HA 
3 months 
RCT (diet vs. waiting list) 
2 months: 400 kcal/d 
1 month: 1000–1200 kcal/d 
Behavior modification 
PA goal of 2 mi/d, 5 d/wk 
16.2 kg (15%) 
decrease in weight 
      
Crosignani  
(2003) 
n=27 
Age 31y, BMI 32.1kg/m2 
OA + PCO 
Variable (≤6 months) 
NRS (single cohort) 
1200 kcal/d 
 
PA goal of 1–2 d/wk 76% of subjects lost 
5–10% body weight 
      
Moran  
(2003) 
n=28 
Age 33y, BMI 37.4kg/m2 
OA + HA 
4 months 
RCT (LP vs. HP; during both 
caloric restriction & WMD) 
3 months: 1400 kcal/d 
1 month: WMD 
HC/LP or LC/HP diets 
Behavior modification 
Supervised PA for 60 
min/wk, with goal of ≥2 
other d/wk 
Cohort: 8 kg (8%) 
decrease in weight 
Decrease in weight in 
LP (7 kg) vs. HP (9 
kg), NS 
      
Hoeger  
(2004) 
n=60 
Age 27y, BMI 40.0kg/m2 
OA + HA 
12 months 
RCT (diet vs. no diet) 
6 months: ≥500 kcal/d deficit 
6 months: WMD 
Low glycemic index foods 
Behavior modification 
PA goal of 150 min/wk 
7 kg decrease in 
weight 
 
      
van Dam  
(2004) 
n=15 
Age 29y, BMI 39.0kg/m2 
OA + HA 
Variable (~7 months) 
NRS (single cohort) 
470 kcal/d N/A ≥10% decrease in 
weight 
      
Moran  
(2006, 2007a) 
n=33 
Age 32y, BMI 34.9kg/m2 
Rotterdam; all phenotypes 
8 months 
RCT (FC vs. CC; WMD) 
2 months: 2 meal 
replacements/d; 1170 kcal/d 
6 months: WMD (FC vs. CC) 
Behavior modification 
PA goal of 8,000 steps/d 
Cohort: 5.6 kg (9%) 
decrease in weight 
Decrease in weight in 
R (6%) vs. NR (7%), 
NS 
      
Moran  
(2007b) 
n=15 
Age 32y, BMI 35.7kg/m2 
Rotterdam; all phenotypes 
2 months 
NRS (PCOS vs. control) 
2 meal replacements/d N/A 3.9 kg (4%) decrease 
in weight 
      
Qublan  
(2007) 
n=21 with OA 
Age 32y, BMI 32.2kg/m2 
Rotterdam; all phenotypes 
Variable (≤6 months) 
NRS (diet vs. metformin) 
1200–1400 kcal/d N/A 4.8 kg/m2 (15%) 
decrease in BMI 
      
Palomba  
(2008) 
n=20 
Age 26y, BMI 33.2kg/m2 
OA + HA + PCO 
6 months 
NRS (diet vs. PA) 
800 kcal/d deficit LC/HP diet 
Behavior modification 
Decrease in weight in 
R (11 kg) vs. NR (2 
kg), p<0.05 
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Table 4.1, continued. 
First Author Population and Diagnosis Study Design Caloric Restriction Additional Approaches Weight Loss 
Thomson  
(2008) 
n=53 with OA 
Age 29y, BMI 36.1kg/m2 
Rotterdam; all phenotypes 
5 months 
RCT (DO vs. DA vs. DC) 
1200–1400 kcal/d LC/HP diet 
Behavior modification 
Supervised PA for 5 d/wk 
Cohort: 9% decrease 
in weight 
Decrease in DO (9%) 
vs. DA (10%) vs. 
DC (8%), NS 
      
Thomson  
(2009) 
n=52 
Age 30y, BMI 36.5kg/m2 
Rotterdam; OA only 
5 months 
NRS (single cohort) 
1400 kcal/d N/A Cohort: 9 kg 
decrease in weight  
Decrease in weight in 
R (12 kg) vs. NR (6 
kg), p<0.05 
      
Palomba  
(2010) 
n=32  
Age 28y, BMI 31.3kg/m2 
OA + HA + PCO 
1.5 months 
RCT (diet vs. clomiphene) 
1000 kcal/d deficit LC/HP diet 
Behavior modification 
Supervised PA for 3 d/wk 
4 kg (5%) decrease in 
weight 
      
Fux Otta  
(2010) 
n=15 
Age 25y, BMI 35.6kg/m2 
OA + HA 
4 months 
RCT (diet vs. metformin) 
1500 kcal/d PA goal of ≥40 min/d, 4 d/wk 1.4 kg/m2 (4%) 
decrease in BMI 
      
Kuchenbecker  
(2011) 
n=32 
Age 25y, BMI 35.6kg/m2 
Rotterdam; OA only 
6 months 
NRS (single cohort) 
≥500 kcal/d deficit Behavior modification 
Individualized PA goals 
Decrease in weight in 
R (6%) vs. NR (3%), 
p<0.05 
      
Ladson  
(2011) 
n=16 
Age 29y, BMI 38.3kg/m2 
OA + HA 
6 months 
RCT (diet vs. metformin) 
500 kcal/d deficit HC/LP diet 
Supervised and 
unsupervised PA, with goal 
of 150 min/wk 
N/A 
      
Nybacka  
(2011, 2013) 
n=43 
Age ~31y, BMI ~36.1kg/m2 
OA + HA + PCO 
4 months 
RCT (diet vs. PA vs. diet/PA) 
≥600 kcal/d deficit HC/LP diet 
Behavior modification 
Individualized PA goals 
Decrease in weight in 
diet (6%) vs. PA 
(3%) vs. diet/PA 
(5%), NS 
      
Pasquali  
(2011) 
n=65 
Age ~23y, BMI ~34.8kg/m2 
OA + HA 
Variable (≥6 months) 
NRS (single cohort) 
6 months: 1200–1400 kcal/d 
Variable follow-up period: WMD 
PA goal of 30 min/d, 5 d/wk Decrease in weight in 
R (16%) vs. NR 
(13%), NS 
Values for clinical characteristics and weight loss are presented as means. Sample sizes refer to the number of women with anovulatory phenotypes at baseline who completed the 
hypocaloric dietary intervention. Where possible, changes in weight are reported for responders (R) versus non-responders (NR) and correspond to data on ovulation presented in 
Table 4.2. “Response” was broadly defined as any improvement in ovulatory or menstrual function. Across studies, behavior modification was defined as interactive individual or group 
education with a health care provider. Abbreviations: OA, oligo-amenorrhea; HA, hyperandrogenism; PCO, polycystic ovaries; IBW, ideal body weight; BMI, body mass index; RCT, 
randomized controlled trial; NRS, non-randomized study; HC/LP, high-carbohydrate/low-protein diet; LC/HP, low-carbohydrate/high-protein diet; FC, fat-counting; CC, carbohydrate-
counting; WMD, weight maintenance diet; PA, physical activity; DO, dietary intervention; DA, dietary intervention with aerobic exercise; DC, dietary intervention with combined aerobic 
and resistance exercise; NS, not significant at p<0.05; N/A, not reported. 
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Dichotomization of Women as Responders and Non-Responders to Dietary Intervention 
Based on these definitions, the ovulatory response to hypocaloric dietary intervention was 
decidedly variable between individuals and across studies (Table 4.2, Columns 6–7). Both 
sporadic and regular ovulations were detected in a wide range of participants with either self-
reported or confirmed menstrual cycle irregularity at baseline. Thirteen to 85% of women 
experienced sporadic ovulation with weight loss and no more than 55% resumed regular ovulatory 
cycles (Table 4.2, Columns 6–7). On average, fewer than three ovulations were detected per 
woman during a six-month dietary intervention.134,135,137 Together, these data imply continued 
cycle irregularity with ovulation occurring at least two months apart. 
In all studies, a subset of women remained anovulatory despite being compliant with the 
dietary intervention (as judged by weight loss) (Table 4.2, Columns 6–7). Hence, women could 
be dichotomized as “responders” and “non-responders” to weight loss. These results could be 
interpreted to mean that dietary intervention is not a universal solution for anovulation in PCOS. 
Yet, it is prudent to consider that variability in the ovulatory response may stem from (a) 
inconsistencies in the measurement of ovulation across studies, (b) heterogeneity in the clinical 
presentation of PCOS or (c) the degree of change in salient endocrine or metabolic features 
during the dietary intervention. The potential impact of each of these factors in the evaluation of 
the ovulatory response to weight loss is addressed in the sections that follow.  
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Table 4.2. Differences in the measurement of ovulation and ovulatory response to hypocaloric dietary intervention across studies in overweight or obese women with PCOS 
First Author Measurement of Ovulation 
Evaluation of Baseline 
Ovulatory Function 
Length of  
Caloric Restriction 
Proportion of Subjects with Evidence 
of Ovulation during Intervention 
 Marker Frequency Marker (Duration)  Sporadic Ovulation Regular Ovulation 
Guzick (1994) Serum P4 Weekly, 8 weeks post-diet Biochemical (2 months)b 3 months 4/6 (67%) N/A 
Crosignani (2003) Serum P4 After self-report of regular menses Not completed Variable (≤6 months) N/A 15/27 (55%) 
Moran (2003) Urinary PDG Twice weekly Menses diary (6 months) 3 months 22/28 (79%) N/A 
Hoeger (2004)a Urinary PDG Weekly Not completed 6 months N/A N/A 
van Dam (2004) Serum P4 Biweekly Biochemical (Once)b Variable (~7 months) 9/15 (60%) N/A 
Moran (2006, 2007a) Urinary PDG Twice weekly Menses diary (6 months) 2 months 28/33 (85%) N/A 
Moran (2007b) Urinary PDG Twice weekly Menses diary (6 months) 2 months 11/15 (73%) N/A 
Qublan (2007) Serum P4 After self-report of regular menses Not completed Variable (≤6 months) 5/21 (24%) N/A 
Palomba (2008) Plasma P4 After spontaneous/induced menses Not completed 6 months 5/20 (25%) N/A 
Thomson (2008) Urinary PDG Twice weekly Biochemical (1 month) 5 months N/A 12/53 (23%) 
Thomson (2009) Urinary PDG Twice weekly Biochemical (1 month) 5 months 10/52 (19%) N/A 
Palomba (2010) Plasma P4 After visualization of CL on TVUS Not completed 1.5 months 4/32 (13%) N/A 
Fux Otta (2010) Serum P4 Uncertain Menses diary (6 months) 4 months 6/15 (40%) N/A 
Kuchenbecker (2011) Serum P4 After self-report of increase in BBT Not completed 6 months 14/32 (44%) N/A 
Ladson (2011)a Urinary PDG Daily Not completed 6 months N/A N/A 
Nybacka (2011, 2013) Serum P4 After self-report of menses Not completed 4 months 15/43 (35%) N/A 
Pasquali (2011) Serum P4 Once pre- and post-diet Biochemical (Once) Variable (6 months) 35/65 (54%) N/A 
Outcomes are reported for women with anovulatory phenotypes prior to dietary intervention. a Data were reported in an inconsistent format compared to other studies and could not 
be extracted. b Results of baseline assessments were reported in the article. Abbreviations: P4, progesterone, PDG, pregnanediol glucuronide; CL, corpus luteum; TVUS, transvaginal 
ultrasonography; BBT, basal body temperature; N/A, not reported. 
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Inconsistencies in the Methods Used to Measure Ovulatory Status 
In line with previous reports,123 the methods used to detect ovulation and characterize any 
reinstatement of ovulatory cyclicity were inconsistent across studies (Table 4.2, Columns 1–3). 
As shown in Table 4.2 (Column 2), the primary markers of ovulation were elevated serum 
concentrations of progesterone or increased urinary excretion of pregnanediol 3-glucuronide 
(PDG). These measurements were consistently performed during the mid-luteal phase of the 
menstrual cycle. Several studies also evaluated urinary estrogens in conjunction with PDG141 or 
considered pregnancy to be sufficient evidence of ovulation in lieu of serum progesterone.136,139  
In both clinical practice and research, a number of techniques are used to confirm the 
occurrence and timing of ovulation. The gold standard method involves direct observation of 
follicular growth and rupture by high-resolution transvaginal ultrasonography.22 If this approach is 
not feasible, then other indirect, but objective, methods may be employed to detect ovulation. 
Such methods include the measurement of pituitary or ovarian hormones in the blood, urine or 
saliva, and the assessment of clinical symptoms including menstrual cycle length or basal body 
temperature (BBT).142,143 In line with these standards, the studies were justified in their common 
use of serum progesterone or urinary PDG (Table 4.2, Column 2); both have been validated as 
reliable and interchangeable markers of ovulation in women with regular menstrual cycles.144 A 
sustained elevation in either biochemical marker is considered sufficient evidence of luteal activity 
and can be detected throughout the luteal phase to the end of the cycle.144 
That being said, the frequency at which these biochemical markers were measured 
differed substantially across studies. Approximately half of the studies (n=8) used an intermittent 
sampling design irrespective of the stage of the menstrual cycle. Assessments were performed 
daily,137 twice weekly,127,132,140,141,145 weekly,134 or biweekly130 to detect ovulation during the dietary 
intervention (Table 4.2, Column 3). By contrast, six studies collected a single blood sample in the 
mid-luteal phase based on morphologic or clinical markers.128,133,135,136,139,146 Of these, only one 
used direct methods to monitor follicle growth and determine ovulation.133 Namely, Palomba and 
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colleagues performed transvaginal ultrasonography at baseline, every four days until visualization 
of a dominant follicle and then daily to follicular collapse. Ovulation was subsequently confirmed 
with plasma progesterone levels.133 The other five studies relied on participant self-report of recent 
spontaneous menses,128,135 resumption of regular menses139,146 or increase in BBT136 (Table 4.2, 
Column 3). When one of these events occurred, the investigators scheduled a blood draw for 
serum progesterone based on an estimation of time to the next luteal phase.128,135,136,139,146 Finally, 
of the remaining three studies, one did not provide adequate information with which to judge the 
frequency of measurements147 and two did not assess ovulation until after the intervention had 
ended129,138 (Table 4.2, Column 3).  
It is probable that the studies with intermittent sampling designs were better positioned to 
capture ovulatory status than the studies that relied on a single biochemical measurement or self-
reported clinical data. The occurrence of ovulation is best ascertained with an intermittent 
sampling design that allows for hormone data to be collected either daily, every-other-day, twice 
weekly, or weekly.148 If one of these approaches is not feasible, a single measurement of serum 
progesterone or urinary PDG in the mid-luteal phase can also be effective to determine whether 
ovulation has occurred.149 However, the reliability of a single measurement to detect ovulation 
during long or unpredictable menstrual cycles, capture peak progesterone concentrations or judge 
luteal phase sufficiency is uncertain. Similar to biochemical methods, prospective menstrual 
diaries and BBT records have been shown to provide reliable estimates of menstrual regularity150 
and the presence of ovulation in healthy women.142,143 Yet, variability in consecutive cycle lengths 
is common150 and ovulation is not an inevitable event during spontaneous menstrual cycles.151 
Infertile patients also demonstrate abnormal fluctuations in BBT during ovulatory cycles, leading 
to errors in the interpretation of temperature charts and prediction of ovulation.152 Given these 
challenges with self-reported clinical data, the choice to schedule blood draws during the 
predicted luteal phase of the next menstrual cycle implies that the first ovulation was never 
biochemically confirmed.128,135,136,139,146 Such approaches may have resulted in a poor estimation 
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of the number of ovulatory cycles, and consequently, a reduced likelihood to accurately report the 
ovulatory response to weight loss.  
There was also marked variability in the methods used to define biochemical evidence of 
ovulation across studies. In the interventions that assessed serum progesterone (Table 4.2, 
Column 2), ovulatory thresholds were always reported and ranged from ≥4 ng/ml (13 nmol/L)147 
to ≥10 ng/ml (32 nmol/L).133,135,146 It was difficult to discern whether these thresholds were 
internally validated or reflected the limits of detection of the various assays used. Two of the 
studies implemented a commercial radioimmunoassay,130,146 but the others did not describe the 
methods employed to measure serum progesterone. By contrast, normative values for PDG were 
not provided by any of the studies that used the marker and the increase in mid-luteal excretion 
was qualitatively assessed.127,128,132,134,140,141,145  
Accordingly, the interpretation of ovulatory status may have been limited by the use of 
inappropriate thresholds for progesterone and PDG to confirm ovulation. In general, a serum 
progesterone concentration of 3.9 ng/ml (12.5 nmol/L) or higher is thought to be presumptive 
evidence of an ovulatory cycle using commonly available commercial assays.149,153 However, all 
of the studies identified thresholds for progesterone that were above this concentration. 
129,130,133,135,136,138,139,146,147 This is interesting, considering that the studies that relied on the highest 
thresholds (≥32 nmol/L) were also the ones to report the smallest proportion of responders to the 
dietary intervention133,135,146 (Table 4.2, Column 6). In addition, there is emerging evidence to 
suggest that luteal phase dynamics of progesterone are altered in obesity70 and PCOS.154 Lower 
urinary excretion and a delayed ovulatory rise in PDG have been noted in obese women with 
regular menstrual cycles,70 and lower luteal concentrations of progesterone have been 
documented in women with ovulatory PCOS compared to healthy controls.154 These findings have 
implications for the detection of spontaneous ovulation in obese anovulatory patients and suggest 
that alternative thresholds may be needed to fully capture ovulatory status in PCOS. 
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Heterogeneity in the Clinical Presentation of PCOS 
The dichotomization of the ovulatory response to hypocaloric dietary intervention likely 
reflects the heterogeneous nature of PCOS. PCOS exists on a spectrum and the diagnosis 
encompasses a broad range of severity of reproductive and metabolic abnormalities.2,89 Such 
differences may impart a variable potential between patients for weight loss to stimulate ovulation. 
To that end, there is utility in identifying the endocrine or metabolic characteristics that distinguish 
responders from non-responders prior to dietary intervention. Nine of the studies evaluated 
baseline clinical predictors of improvements in reproductive function. 125,126,128,130,136,138,140,141,145  
Response was defined in one of two ways across studies: (1) evidence of sporadic 
ovulation or (2) improved menstrual cyclicity following dietary intervention. None of the studies 
assessed predictors of the transition to normal ovulatory function. Improvements in menstrual 
cyclicity were broadly characterized as a decrease in menstrual cycle irregularity, shift from 
irregular to regular menstrual cycles or shift from anovulatory to ovulatory cycles.125,126,128,140,141,145 
Increased cycle regularity was not necessarily accompanied by improvements in ovulation and a 
shift from anovulatory to ovulatory cycles appeared to reflect evidence of sporadic, rather than 
regular, ovulation.125,141,145 In addition, one study evaluated women with partial or complete 
recovery from PCOS and identified baseline features associated with the collective normalization 
of hirsutism, ovulation and menstrual cyclicity.138  
As shown in Table 4.3, six of the nine studies identified significant clinical predictors of 
improved reproductive outcomes following dietary intervention.125,126,128,130,138,145 The baseline 
characteristics that emerged were largely markers of androgen excess and adiposity. Overall, 
women with lower circulating concentrations of sex hormone binding globulin,130 testosterone,128 
androstenedione,138 and anti-Müllerian hormone (AMH)125,126,145 were more likely to experience 
sporadic ovulation and improved menstrual cyclicity during dietary intervention. A lower waist 
circumference and waist-to-hips ratio were also predictive of recovery from the syndrome.138 
Taken together, these findings suggest that obese women with milder ovarian dysfunction at 
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baseline may be more likely to experience reproductive benefit from hypocaloric dietary 
intervention (Table 4.3).  
That being said, only three studies directly focused on clinical predictors of ovulation, and 
of these, two could not identify baseline differences between responders and non-
responders.126,136 Despite their associations with improved menstrual cyclicity, neither androgens 
nor AMH predicted ovulation following dietary intervention126,136 (Table 4.3). Inconsistencies in the 
ability to identify baseline predictors of ovulatory response may have been impacted by two 
important factors. 
First, “response” was broadly defined as an improvement in ovulation or menstrual 
cyclicity compared to baseline. However, very few studies assessed baseline ovulatory status in 
their participants (Table 4.2, Column 4). Among the studies that did, serum progesterone or 
urinary PDG were measured at a single time point130,138 or on a serial basis for up to two months 
prior to intervention.129,140,145 Alternatively, some participants were asked to keep menstrual 
diaries for one to six months.127,132,140,141,145,147 While these direct and indirect markers of ovulation 
were likely used as a reference for improvement, only two of the studies actually published the 
data that were collected129,130 (Table 4.2, Column 4). As a result, it was difficult to confirm that the 
reported changes constituted an improvement compared to baseline and a missed opportunity 
was noted to characterize variability in the degree of ovulatory response among women. The latter 
points to some uncertainty that a single baseline characteristic could predict a broad spectrum of 
reproductive improvements following dietary intervention.  
Second, the use of different diagnostic criteria to define study populations resulted in the 
assessment of ovulatory response across multiple phenotypes (Table 4.1, Column 2). The most 
commonly accepted criteria for the diagnosis of PCOS (2003 Rotterdam Criteria) identify four 
distinct clinical phenotypes: (1) Frank (oligomenorrhea, hyperandrogenism and polycystic 
ovaries), (2) Non-PCO (oligomenorrhea, hyperandrogenism and normal ovaries), (3) Ovulatory 
(regular menses, hyperandrogenism and polycystic ovaries), and (4) Normoandrogenic or “Mild” 
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(oligomenorrhea, normal androgen status and polycystic ovaries).8,9 There is substantial evidence 
that the severest variants of the condition are Frank and Non-PCO PCOS (phenotypes which are 
also recognized by the 1990 NIH Criteria).2,17 Women with combined oligomenorrhea and 
hyperandrogenism have the most profound disturbances in gonadotropin dynamics, ovarian 
androgen production and insulin sensitivity, independent of obesity.11,155,156 By contrast, the other 
phenotypes seem to represent milder variants of the condition. Women with Ovulatory and 
Normoandrogenic PCOS have endocrine disturbances that are intermediate to Frank PCOS and 
healthy controls,11,155,156 and the presence of metabolic abnormalities seems to depend on the 
degree of abdominal adiposity.13 Collectively, these differences suggest that variable 
improvements in endocrine and metabolic abnormalities may be needed to restore ovulatory 
cyclicity across phenotypes.  
PCOS was diagnosed according to the NIH criteria in seven studies129,130,134,137,138,141,147 
and the Rotterdam criteria in 10 studies (Table 4.1, Column 2). Of the interventions that used the 
broader definition, three primarily recruited the Frank and Non-PCO phenotypes.128,135 The 
inclusion of these two phenotypes implies that the majority of participants had the severest 
manifestations of the condition and met both the NIH and Rotterdam criteria for PCOS. The 
remaining studies (n=7) evaluated ovulatory response across more heterogeneous cohorts. Of 
these, four enrolled participants who could be stratified into any of the recognized phenotypes, 
and as such, included women with evidence of regular ovulation and menstrual cycles at 
baseline.127,132,140,146 In some cases, these studies presented outcome data on ovulation for the 
entire cohort and did not distinguish the women with histories of anovulation from those with 
normal ovulatory function prior to the intervention127,132 (Table 4.1, Column 2). The combined 
assessment of ovulatory status in these distinct cohorts may have masked the independent effect 
of dietary intervention on ovulation, since improvements would have been challenging to 
characterize in women with existing ovulatory cyclicity. The other three studies enrolled 
anovulatory women irrespective of androgen status.136,139,145 Crosignani and colleagues required 
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participants to demonstrate combined evidence of chronic anovulation or amenorrhea and 
polycystic ovarian morphology.139 The absence of inclusion criteria or data to corroborate 
androgen excess suggested that the cohort was largely comprised of women with the 
normoandrogenic phenotype.139 By contrast, Thomson et al. and Kuchenbecker et al. screened 
for hyperandrogenism and the resulting cohorts appeared to include all variants except Ovulatory 
PCOS136,145 (Table 4.1, Column 2). It is possible that weight loss would have differential effects 
on ovarian androgen production in normo- compared to hyperandrogenic phenotypes and that 
such differences would be difficult to capture using these definitions.  
91 
Table 4.3. Baseline endocrine and metabolic characteristics linked to improved reproductive outcomes after hypocaloric dietary intervention in overweight or obese women with PCOS 
Outcome Baseline Characteristic of Respondersa Study 
Sporadic ovulation None Kuchenbecker et al., 2011; Nybacka et al., 2013 
 Higher SHBG van Dam et al., 2004 
Regular (monthly) ovulation None None 
Improved menstrual cyclicity None Moran et al., 2003; Thomson et al., 2008 
 Lower AMH Moran et al., 2007a; Thomson et al., 2009; Nybacka et al., 2013 
 Lower testosterone Nybacka et al., 2011 
Recovery from PCOS Lower androstenedione Pasquali et al., 2011 
 Lower waist circumference and WHR Pasquali et al., 2011 
a vs. non-responders. Abbreviations: SHBG, sex hormone binding globulin; AMH, anti-Müllerian hormone; WHR, waist-to-hips ratio. 
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Degree of Change in Salient Endocrine or Metabolic Features Afforded by the Intervention  
The dichotomization of ovulatory response to weight loss may also reflect the ability of 
hypocaloric dietary intervention to recover the endocrine and metabolic abnormalities that impair 
antral follicle development. Currently, little is known about the salient features or degree of change 
required to improve reproductive outcomes with weight loss in PCOS.  
Ten studies evaluated differences in clinical, endocrine and metabolic characteristics 
between responders and non-responders at the end of the dietary intervention125,128,130,134–
136,138,140,145 (Table 4.4). Compared to non-responders, women with ovulatory or menstrual 
improvements after weight loss demonstrated greater reductions in weight or BMI, central 
adiposity, hirsutism or hyperandrogenemia and indices of insulin resistance.125,128,130,134–
136,138,140,141,145 Changes in gonadotropins and ovarian hormones were similar between 
groups130,135,138,140,145 (Table 4.4). Hence, the body of evidence suggests that improvements in 
weight, adiposity, androgens, and insulin are the primary mediators of restored ovulatory function 
after hypocaloric dietary intervention in PCOS (Figure 4.1). 
Nevertheless, it is prudent to consider that these analyses produced inconsistent results 
across studies. While the majority of authors noted greater changes among responders, a 
substantial portion (37–40%) were unable to identify significant differences in weight, 
hyperandrogenism or insulin sensitivity between groups125,130,140,145 (Table 4.4). These findings 
could reflect heterogeneity in the study populations (as described above) or a larger issue 
surrounding the efficacy of the interventions that were used.  
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Table 4.4. Studies that have linked changes in clinical, endocrine, and metabolic characteristics to improved reproductive outcomes after hypocaloric dietary intervention in overweight 
or obese women with PCOS 
 
Outcome 
Number of studies that found  
greater changes in respondersa  
Number of studies that found  
no differences in respondersa 
Decrease in weight or BMI 5/8 (63%) 3/8 (37%) 
Decrease in central adiposity 5/6 (83%) 1/6 (17%) 
Decrease in hirsutism or hyperandrogenemia 3/5 (60%) 2/5 (40%) 
Improvement in insulin sensitivity 5/8 (63%) 3/8 (37%) 
Decrease in mean concentrations of gonadotropins or ovarian hormonesb 1/4 (25%) 3/4 (75%) 
a vs. non-responders. b Includes luteinizing hormone; follicle stimulating hormone; estradiol; progesterone; anti-Müllerian hormone.  
94 
The primary therapeutic targets of caloric restriction are weight and adiposity.124 In PCOS, 
it is likely that changes in weight and adiposity stimulate improvements in androgens and insulin, 
which together precede ovulation and menses.127 If sufficient weight loss is not achieved, then it 
follows that improvements in ovulatory function would be unlikely to occur (Figure 4.1). In the 
studies included for review, women experienced sporadic ovulation with modest changes in 
weight (i.e. <16%) (Table 4.1 and 4.2). This occurred despite the fact that most women were still 
classified as obese (BMI ≥30 kg/m2) at the end of the various dietary interventions.128,130,134,136,147 
A greater degree of weight loss, resulting in a healthier BMI, may be necessary to fully restore 
ovulatory cyclicity in obese women with PCOS. This idea is supported by preliminary evidence 
from studies involving bariatric surgery, wherein 100% of anovulatory patients resumed regular 
ovulation and menses after a 41-kg reduction in weight.157 However, surgical approaches for 
weight loss have been associated with significant risks, including post-operative complications, 
nutritional deficiencies and increased likelihood for deleterious fetal outcomes during 
pregnancy.158 Therefore, it is considered wisest to first advocate for dietary and lifestyle 
modifications in obese women with PCOS.158 Further studies are needed to determine the optimal 
degree of weight loss to induce and sustain improvements in ovulatory function, so as to better 
tailor dietary interventions to individual needs.  
In addition, little is known about the time course of caloric restriction that is required to 
improve ovarian function in obese women with PCOS. Although serial assessments of ovulatory 
status were performed, the majority of studies did not report the time point(s) of the intervention 
at which ovulation was observed. Only three studies provided information on this outcome. From 
these data, it appeared unlikely for an ovarian response to occur within the first two weeks of a 
dietary intervention.130,133,141 Specifically, Moran and colleagues did not detect sporadic ovulation 
until weeks 4–6 or 12–13 of caloric restriction.141 The time course of these observations may be 
explained by evidence that endocrine and metabolic responses to caloric restriction precede 
ovulation.127,130 Alterations in neuroendocrine feedback were identified in as a few as seven days 
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on a very low calorie diet,130 and significant improvements in androgen excess and insulin 
sensitivity were documented within 2–4 weeks after the onset of dietary intervention.127 
Consequently, a decrease in insulin-mediated androgen production92 might be expected to 
stimulate sporadic selection and ovulation several weeks later.127 
Despite the occurrence of sporadic ovulation, it remains unclear whether short-term caloric 
restriction is sufficient to normalize ovulatory cyclicity in obese women with PCOS. It has been 
suggested that turnover of the antral follicles recruited under hyperandrogenic and insulin 
resistant conditions precedes improvements in ovarian function.145 Changes in the mechanisms 
of selection and ovulation may not manifest until a new cohort of follicles is activated from the 
primordial pool under an improved hormonal environment. Given that a pre-antral follicle takes 
approximately three months to reach its pre-ovulatory diameter,33 it is possible that some of the 
dietary interventions were too short to realize improvements in reproductive function145 (Table 
4.1). Further investigation is needed to determine the precise time course of caloric restriction 
that is required to normalize ovulatory cyclicity in PCOS.  
It is also uncertain whether improvements in ovulatory function can be sustained after a 
hypocaloric dietary intervention is discontinued. In general, weight maintenance is challenging 
and weight re-gain is a common problem across populations.159 This is essential to address in the 
context of PCOS, as any increase in weight could recover initial endocrine and metabolic 
disturbances and lead to the rebound of anovulation. Five studies performed follow-up 
assessments and attempted to capture these changes after the dietary intervention.127,128,134,138,141 
Follow-up assessments were performed on a cross-sectional basis128,138 or as part of a weight-
maintenance intervention that involved regular visits to the research unit.127,134,141 Ovulatory or 
menstrual status was largely measured at each time point.127,128,134,141 Yet, only two of the studies 
distinguished the data that were collected at the follow-up visits from those collected during the 
intervention, and menstrual status was the primary reproductive outcome of interest.128,141 
Specifically, Moran and colleagues found that improvements in menstrual cyclicity were sustained 
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for 4–6 months after caloric restriction in the majority of patients.141 In some cases, women 
reported regular menses for an average of two years after the end of the intervention.128 These 
outcomes occurred independent of increased energy intake141 or weight gain.128,141 Further 
studies are needed to clarify whether and how these sustained changes in menstrual cyclicity are 
reflected in the ovaries.  
Despite ambiguity surrounding the ideal dietary intervention, current dogma stipulates that 
caloric restriction is the primary facilitator of weight loss and ovulation in obese women with 
PCOS.62,121 Consequently, dietary interventions involving caloric restriction were highlighted in 
this review. However, it is important to acknowledge that most of the included studies prescribed 
caloric restriction as part of a larger multifactorial intervention (Table 4.1, Column 5). Emerging 
data suggest that tailored macronutrient composition, physical activity, and/or behavior 
modification therapy can augment the effect of caloric restriction on ovulatory function.121,160 While 
these additional approaches were not addressed in this review, they have been described 
extensively by Moran et al.121 and Harrison et al.160 Ultimately, well-designed, randomized 
controlled trials are still required to determine whether multifactorial dietary interventions can 
further improve reproductive outcomes in PCOS.121,160 
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CONCLUSION 
In summary, commendable progress has been made towards understanding the impact 
of caloric restriction on ovulatory function in obese women with PCOS. It is clear that modest 
weight loss is associated with the occurrence of sporadic ovulation in a meaningful proportion of 
patients and that reductions in hyperandrogenism and insulin resistance likely precede any 
improvements in reproductive outcomes. The ovulatory response may also depend on the 
presence of milder reproductive dysfunction at baseline and a greater degree of change in 
endocrine and metabolic features with intervention. Nevertheless, this review highlighted the 
variability in the ovulatory response to weight loss and found little evidence to support the 
effectiveness of hypocaloric dietary intervention to restore normal ovulatory function in PCOS. 
Because resumption of regular ovulatory cycles may not be a realistic goal for all patients, 
healthcare providers should be judicious in counseling the degree to which weight loss can be 
expected to improve ovulatory function in obese patients with PCOS. Future studies would benefit 
from efforts to improve the accuracy and consistency of measures used to determine and report 
ovulatory status both at baseline and during dietary intervention. The use of intermittent sampling 
of biochemical markers, assessment of alternative thresholds for ovulation to better judge luteal 
function in PCOS, and distinction of ovulation from menstrual cyclicity in reporting improvements 
is recommended. Finally, the impact of phenotypic variation on the ovulatory response to weight 
loss should be addressed in order to fully capture the degree and duration of caloric restriction 
that is needed to effectively promote weight loss and ovulation in PCOS. The identification of 
optimal dietary and lifestyle approaches to treat anovulation will improve the health and wellbeing 
of obese women living with PCOS.  
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SUMMARY AND FUTURE DIRECTIONS 
 
For decades, clinicians and researchers have relied on evidence from histologic studies 
of folliculogenesis to guide the diagnosis of polycystic ovary syndrome (PCOS) and selection of 
treatment strategies for anovulation. The notion that follicular excess, arrest, and persistence are 
universal phenomena in this condition is outdated and needed re-consideration. This work has 
consolidated the role of ovarian ultrasonography as an effective tool to determine the degree to 
which antral follicle development is impaired in PCOS. Major findings and implications of this 
research are summarized below.  
Importantly, we demonstrated the feasibility of capturing antral follicle growth and 
regression on ultrasonography in women with heightened follicle populations (Chapter 1). 
Polycystic ovaries contained more than 100 follicles on any given day of the study. Yet, it was 
possible to count individual follicles and follow their unique growth trajectories over time. Our 
approaches were effective44,75 and consequently hold promise for future evaluations of antral 
follicle development – both in PCOS and other anovulatory conditions.  
We concluded that follicular excess is a constant feature during anovulatory (Chapter 1) 
and sporadic ovulatory cycles (Chapter 2) (Figure S.1). This finding affirms our other recent work, 
which has shown that sonographic metrics related to follicle number have significant potential to 
detect PCOS.66,93 From a clinical perspective, the permanence of follicular excess over time has 
implications for scheduling diagnostic evaluations of PCOS and reducing undue burden on 
patients. Our data suggest that menstrual cycle status has little bearing on the ability of follicle 
number to reflect the condition of PCOS and that random evaluations of ovarian morphology are 
appropriate (Chapter 3). Substantial inter-individual, but not intra-cycle, variation in follicular 
excess (Chapter 1 and 3) may point to the potential of the ovary to serve as a consistent 
biomarker of reproductive dysfunction.88 Importantly, it remains unclear whether follicular excess 
remains a salient feature across the reproductive lifespan in PCOS. Such an abnormality may 
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originate in utero or the pubertal transition,161 but resolve during menopause, as the ovarian 
reserve depletes.162 Further studies are needed to understand these changes and whether age-
specific diagnostic criteria are needed in this condition. 
We confirmed that follicles become “arrested” at the mid-antral stage in polycystic ovaries, 
but revealed that they also turnover more often than follicles in normal ovaries. This knowledge 
challenges the traditional theory of follicular persistence and provides a new model of antral follicle 
development in PCOS (Chapter 1) (Figure S.1). These data are likely to inform the selection of 
pharmacologic protocols for anovulation, since exogenous hormones (e.g. recombinant follicle-
stimulating hormone, FSH) may accelerate these processes and place women at increased risk 
for adverse health and pregnancy-related outcomes. 
 
Figure S.1. Proposed new model of impaired antral folliculogenesis in PCOS. The revised 
theories for disruptions in recruitment, selection, and ovulation are depicted. Up and down arrows 
refer to increased and decreased activity, respectively, and “X’s” refer to absent events. 
Remaining gaps in knowledge are identified with question marks. Follicular graphics were 
obtained from Ansh Labs. 
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We showed that disordered folliculogenesis in PCOS occurs on a spectrum from mild to 
severe, just like the clinical and biochemical features of the syndrome. Numerous follicles 
randomly emerge and regress over time and do not demonstrate the same organized patterns of 
recruitment as in healthy women (Chapter 1). Follicles can occasionally emerge from this disorder 
and progress to ovulation, but also exhibit altered growth kinetics, which may signal other 
disruptions in ovulatory function (Chapter 2). Together, these studies identified potential defects 
in follicular recruitment (Chapter 1) and selection in PCOS (Chapter 1). Additional analyses, 
coupled with serial endocrine dynamics, are ongoing to comprehensively capture the extent of 
impaired folliculogenesis in this condition (Figure S.1).  
Ultimately, these data hold promise for understanding the variability in the ovulatory 
response to hypocaloric dietary intervention in women with PCOS (Chapter 4). Through our 
narrative review of the literature, we documented that weight loss is associated with the 
occurrence of sporadic ovulation – but not ovulatory cyclicity, which is likely the more important 
outcome measure. However, our assessment of sporadic ovulations in PCOS (Chapter 2) 
highlighted a need for further studies to understand the implications of altered growth kinetics on 
oocyte quality, luteal function, and/or endometrial receptivity. Moreover, our assessment of the 
available evidence points to a favorable effect of weight loss on ovulation in some (responders), 
but not all, patients (non-responders). Similar to our findings in Chapter 2, we noted that the 
ovulatory response may depend on milder reproductive dysfunction at baseline. Future studies, 
that use accurate methods to detect ovulation, and new knowledge of altered follicular growth in 
PCOS, are ultimately needed to determine the effectiveness of hypocaloric dietary intervention to 
normalize the spectrum of disordered antral folliculogenesis in PCOS (Chapter 1).  
Together, these projects provide new insight into the mechanism of anovulation in PCOS 
(Figure S.1). Our use of ultrasonography enables the immediate translation of our findings into 
clinical practice to improve the diagnosis and management of women affected by this highly 
prevalent, broad spectrum endocrine disorder.
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